ET0014_13Mar18 V 1.6 Epo-Tbi_Nni Picf.en-SG_zh-SG.L1-T1

```json
{
  "combined_segments": [
    {
      "s": "You have been enrolled in this research project in accordance with Singapore law which allows the patient's spouse, parent, guardian or legal representative to consent to the patient taking part in medical research where the patient is unable to provide consent for himself/herself. Your legally acceptable representative consented to your taking part in this research at a time when you were unable to consent for yourself. You are now invited to consider whether you wish to continue taking part in this research project.",
      "t": "您是一位中度或重度创伤性脑损伤（TBI）患者的负责人。新加坡法律允许患者的配偶、父母、监护人或合法代表在患者无法自行表达同意的情况下同意让患者参加医学研究。因此，我们要求您同意您的亲友（患者）参加一项试验 TBI 新疗法的研究项目。这种新疗法是一种称为\"促红细胞生成素\"的药物。",
      "c": 0.85,
      "m": "Combined three sentences that form a coherent legal context about consent procedures and the current invitation to continue participation. The target translation restructures this into a more concise explanation for the legal representative context.",
      "sl": 12,
      "tl": 12
    },
    {
      "s": "The aim of this study is to determine if EPO reduces secondary brain injury and helps patients make a better recovery after traumatic brain injury. We also plan to monitor the effect of EPO on the rate of deep vein thrombosis (DVT - blood clots in the large veins, usually in the legs) in patients with moderate or severe TBI in the intensive care unit (ICU).",
      "t": "本研究旨在确定 EPO 是否能够减少继发性脑损伤并帮助患者在遭受创伤性脑损伤之后更好地康复。我们还计划监测 EPO 对于入住重症监护病房（ICU）的中度或重度 TBI 患者深静脉血栓形成（DVT - 大静脉中的血凝块，常见于腿部）发生率的影响。",
      "c": 0.95,
      "m": "Combined two sentences that together describe the dual objectives of the study - both the primary aim and the secondary monitoring objective, forming a complete study purpose statement.",
      "sl": 26,
      "tl": 26
    },
    {
      "s": "EPO has been approved for use for other purposes in Australia for some years. It is used for the treatment of anaemia (low blood count) in patients who are on kidney dialysis for a long time, patients who have had a major operation and patients on treatment for cancer. However, it is not approved for use in TBI patients.",
      "t": "EPO 在澳洲获准用于其他用途已有若干年，它被用于治疗长期接受洗肾、动过大手术及接受癌症治疗的患者的贫血症（血细胞计数低）。不过，它尚未获准用于 TBI 患者。",
      "c": 0.9,
      "m": "Combined three sentences that provide background on EPO's approved uses and its experimental status for TBI, forming a coherent context about the drug's regulatory status.",
      "sl": 27,
      "tl": 27
    },
    {
      "s": "The study is double-blind because we need to work out whether or not the study drug is effective. To do this we need to be able to compare two groups of people by randomly assigning them to receive either the EPO or placebo. Double-blind means that neither you, nor your legally acceptable representative nor the study staff will know what treatment is given to you.",
      "t": "本研究采用双盲法是因为我们需要确定研究药物是否有效。为此，我们需要通过随机指定两组人群分别接受 EPO 或安慰剂，来对其进行对比。双盲意味着，不论是您、患者还是研究人员都不会知道患者将接获什么疗法。",
      "c": 0.92,
      "m": "Combined three sentences that explain the rationale and meaning of double-blind methodology in a logical sequence.",
      "sl": 29,
      "tl": 29
    },
    {
      "s": "The injection was given in the upper arm, thigh or abdomen (tummy). You had a 1 in 2 or 50% chance of receiving EPO. The injection was given again on days 8 and 15 if you stayed in the ICU over this time. If you were discharged to the general ward no further doses were given.",
      "t": "注射部位为上臂、大腿或腹部（肚子）。患者将有二分之一或 50% 的几率接获 EPO。如果患者在这段时间住在ICU，注射则将在第 8 天和第 15 天再次进行。如果患者已转到普通病房，则无须给予更多剂量。",
      "c": 0.94,
      "m": "Combined four sentences that describe the complete injection protocol including location, probability, timing, and discharge conditions in a cohesive treatment description.",
      "sl": 40,
      "tl": 40
    },
    {
      "s": "Support stockings or compression pads wrapped around the legs were ordered by the doctor. When bleeding after the injury had settled, blood thinning medication was commenced. These treatments described are part of standard care for TBI patients.",
      "t": "医生会要求使用护腿长袜或裹在腿部的压缩垫。当损伤之后的出血问题解决后，将开始使用血液稀释药物。上述这些治疗都是 TBI 患者标准护理的一部分。",
      "c": 0.93,
      "m": "Combined three sentences that form a complete description of standard clot prevention treatments for TBI patients.",
      "sl": 42,
      "tl": 42
    }
  ],
  "combined_segments_split": [
    {
      "s": "You have been enrolled in this research project in accordance with Singapore law which allows the patient's spouse, parent, guardian or legal representative to consent to the patient taking part in medical research where the patient is unable to provide consent for himself/herself.",
      "t": "新加坡法律允许患者的配偶、父母、监护人或合法代表在患者无法自行表达同意的情况下同意让患者参加医学研究。",
      "c": 0.9,
      "m": "Split from combined segment - legal basis for representative consent",
      "sl": 12,
      "tl": 12
    },
    {
      "s": "Your legally acceptable representative consented to your taking part in this research at a time when you were unable to consent for yourself.",
      "t": "因此，我们要求您同意您的亲友（患者）参加一项试验 TBI 新疗法的研究项目。",
      "c": 0.85,
      "m": "Split from combined segment - representative's consent action",
      "sl": 12,
      "tl": 12
    },
    {
      "s": "You are now invited to consider whether you wish to continue taking part in this research project.",
      "t": "这种新疗法是一种称为\"促红细胞生成素\"的药物。",
      "c": 0.8,
      "m": "Split from combined segment - current invitation to continue (note: target restructured this information)",
      "sl": 12,
      "tl": 12
    },
    {
      "s": "The aim of this study is to determine if EPO reduces secondary brain injury and helps patients make a better recovery after traumatic brain injury.",
      "t": "本研究旨在确定 EPO 是否能够减少继发性脑损伤并帮助患者在遭受创伤性脑损伤之后更好地康复。",
      "c": 0.95,
      "m": "Split from combined segment - primary study aim",
      "sl": 26,
      "tl": 26
    },
    {
      "s": "We also plan to monitor the effect of EPO on the rate of deep vein thrombosis (DVT - blood clots in the large veins, usually in the legs) in patients with moderate or severe TBI in the intensive care unit (ICU).",
      "t": "我们还计划监测 EPO 对于入住重症监护病房（ICU）的中度或重度 TBI 患者深静脉血栓形成（DVT - 大静脉中的血凝块，常见于腿部）发生率的影响。",
      "c": 0.95,
      "m": "Split from combined segment - secondary monitoring objective",
      "sl": 26,
      "tl": 26
    },
    {
      "s": "EPO has been approved for use for other purposes in Australia for some years.",
      "t": "EPO 在澳洲获准用于其他用途已有若干年，",
      "c": 0.92,
      "m": "Split from combined segment - EPO approval history",
      "sl": 27,
      "tl": 27
    },
    {
      "s": "It is used for the treatment of anaemia (low blood count) in patients who are on kidney dialysis for a long time, patients who have had a major operation and patients on treatment for cancer.",
      "t": "它被用于治疗长期接受洗肾、动过大手术及接受癌症治疗的患者的贫血症（血细胞计数低）。",
      "c": 0.93,
      "m": "Split from combined segment - approved uses of EPO",
      "sl": 27,
      "tl": 27
    },
    {
      "s": "However, it is not approved for use in TBI patients.",
      "t": "不过，它尚未获准用于 TBI 患者。",
      "c": 0.95,
      "m": "Split from combined segment - experimental status for TBI",
      "sl": 27,
      "tl": 27
    },
    {
      "s": "The study is double-blind because we need to work out whether or not the study drug is effective.",
      "t": "本研究采用双盲法是因为我们需要确定研究药物是否有效。",
      "c": 0.93,
      "m": "Split from combined segment - rationale for double-blind design",
      "sl": 29,
      "tl": 29
    },
    {
      "s": "To do this we need to be able to compare two groups of people by randomly assigning them to receive either the EPO or placebo.",
      "t": "为此，我们需要通过随机指定两组人群分别接受 EPO 或安慰剂，来对其进行对比。",
      "c": 0.94,
      "m": "Split from combined segment - comparison methodology",
      "sl": 29,
      "tl": 29
    },
    {
      "s": "Double-blind means that neither you, nor your legally acceptable representative nor the study staff will know what treatment is given to you.",
      "t": "双盲意味着，不论是您、患者还是研究人员都不会知道患者将接获什么疗法。",
      "c": 0.95,
      "m": "Split from combined segment - definition of double-blind",
      "sl": 29,
      "tl": 29
    },
    {
      "s": "The injection was given in the upper arm, thigh or abdomen (tummy).",
      "t": "注射部位为上臂、大腿或腹部（肚子）。",
      "c": 0.96,
      "m": "Split from combined segment - injection locations",
      "sl": 40,
      "tl": 40
    },
    {
      "s": "You had a 1 in 2 or 50% chance of receiving EPO.",
      "t": "患者将有二分之一或 50% 的几率接获 EPO。",
      "c": 0.96,
      "m": "Split from combined segment - probability of receiving EPO",
      "sl": 40,
      "tl": 40
    },
    {
      "s": "The injection was given again on days 8 and 15 if you stayed in the ICU over this time.",
      "t": "如果患者在这段时间住在ICU，注射则将在第 8 天和第 15 天再次进行。",
      "c": 0.95,
      "m": "Split from combined segment - repeat injection schedule",
      "sl": 40,
      "tl": 40
    },
    {
      "s": "If you were discharged to the general ward no further doses were given.",
      "t": "如果患者已转到普通病房，则无须给予更多剂量。",
      "c": 0.96,
      "m": "Split from combined segment - discharge condition",
      "sl": 40,
      "tl": 40
    },
    {
      "s": "Support stockings or compression pads wrapped around the legs were ordered by the doctor.",
      "t": "医生会要求使用护腿长袜或裹在腿部的压缩垫。",
      "c": 0.94,
      "m": "Split from combined segment - mechanical clot prevention",
      "sl": 42,
      "tl": 42
    },
    {
      "s": "When bleeding after the injury had settled, blood thinning medication was commenced.",
      "t": "当损伤之后的出血问题解决后，将开始使用血液稀释药物。",
      "c": 0.93,
      "m": "Split from combined segment - pharmacological clot prevention",
      "sl": 42,
      "tl": 42
    },
    {
      "s": "These treatments described are part of standard care for TBI patients.",
      "t": "上述这些治疗都是 TBI 患者标准护理的一部分。",
      "c": 0.95,
      "m": "Split from combined segment - standard care context",
      "sl": 42,
      "tl": 42
    }
  ],
  "sentence_segments": [
    {
      "s": "Patient Information and Consent Form",
      "t": "患者信息及同意书",
      "c": 0.98,
      "m": "Document title",
      "sl": 1,
      "tl": 1
    },
    {
      "s": "(Consent to Continue)",
      "t": "（合法代表）",
      "c": 0.85,
      "m": "Subtitle - note target adaptation for legal representative context",
      "sl": 2,
      "tl": 2
    },
    {
      "s": "Full Project Title: A randomised, placebo-controlled trial of erythropoietin in ICU patients with traumatic brain injury",
      "t": "完整项目名称： 使用促红细胞生成素治疗创伤性脑损伤 ICU 患者的随机化、安慰剂对照试验",
      "c": 0.96,
      "m": "Full project title",
      "sl": 3,
      "tl": 3
    },
    {
      "s": "ErythroPOietin in Traumatic Brain Injury: \"EPO – TBI\"",
      "t": "使用促红细胞生成素治疗创伤性脑损伤：\"EPO – TBI\"",
      "c": 0.97,
      "m": "Project acronym and full name",
      "sl": 4,
      "tl": 4
    },
    {
      "s": "Principal Investigator: Dr Ng Wai Hoe (NNI) Dr Tan Hui Ling (TTSH)",
      "t": "首席研究员： Ng Wai Hoe 医生（NNI） Tan Hui Ling 医生（TTSH）",
      "c": 0.98,
      "m": "Principal investigators",
      "sl": 5,
      "tl": 5
    },
    {
      "s": "Sites: National Neuroscience Institute Tan Tock Seng Hospital",
      "t": "地点： 国立脑神经医学院 陈笃生医院",
      "c": 0.97,
      "m": "Study sites",
      "sl": 6,
      "tl": 6
    },
    {
      "s": "11 Jalan Tan Tock Seng 11 Jalan Tan Tock Seng",
      "t": "11 Jalan Tan Tock Seng 11 Jalan Tan Tock Seng",
      "c": 1.0,
      "m": "Address information",
      "sl": 7,
      "tl": 7
    },
    {
      "s": "Singapore 308433 Singapore 308433",
      "t": "Singapore 308433 Singapore 308433",
      "c": 1.0,
      "m": "Postal code",
      "sl": 8,
      "tl": 8
    },
    {
      "s": "Version number: 1.6 Date: 18 March 2013",
      "t": "版本号： 1.6 日期： 2013 年 3 月 18 日",
      "c": 0.98,
      "m": "Version and date information",
      "sl": 10,
      "tl": 10
    },
    {
      "s": "Introduction",
      "t": "简介",
      "c": 0.95,
      "m": "Section heading",
      "sl": 11,
      "tl": 11
    },
    {
      "s": "You are invited to continue to take part in this research project because you have a moderate or severe traumatic brain injury (TBI).",
      "t": "本《患者信息及同意书（合法代表）》将告诉您有关该研究项目的情况。",
      "c": 0.8,
      "m": "Reason for invitation - note target restructures for legal representative",
      "sl": 13,
      "tl": 13
    },
    {
      "s": "The research project is testing a new treatment for TBI.",
      "t": "它阐述了所涉及的试验和治疗。",
      "c": 0.85,
      "m": "Research purpose - target restructured",
      "sl": 13,
      "tl": 13
    },
    {
      "s": "The new treatment is a medication called erythropoietin.",
      "t": "了解所涉及的内容将帮助您决定患者是否应参加研究。",
      "c": 0.7,
      "m": "Treatment description - target restructured for decision context",
      "sl": 13,
      "tl": 13
    },
    {
      "s": "Please read this information carefully.",
      "t": "请仔细阅读本信息文件。",
      "c": 0.96,
      "m": "Instruction to read carefully",
      "sl": 14,
      "tl": 14
    },
    {
      "s": "Ask questions about anything that you don't understand or want to know more about.",
      "t": "如果您有不明白的地方或想要了解更多详情，请尽管提问。",
      "c": 0.94,
      "m": "Encouragement to ask questions",
      "sl": 14,
      "tl": 14
    },
    {
      "s": "Before deciding whether or not you should continue to take part, you might want to talk about it with a relative, friend or your local doctor.",
      "t": "在决定患者是否应参加之前，您可能想要与亲属、朋友或您当地的医生讨论。",
      "c": 0.92,
      "m": "Suggestion to consult others before deciding",
      "sl": 14,
      "tl": 14
    },
    {
      "s": "Participation in this research is voluntary.",
      "t": "本研究为自愿参加。",
      "c": 0.97,
      "m": "Voluntary participation statement",
      "sl": 15,
      "tl": 15
    },
    {
      "s": "If you don't wish to continue to take part, you don't have to.",
      "t": "如果您不希望患者参加，则患者不必参加。",
      "c": 0.95,
      "m": "Right to decline participation",
      "sl": 15,
      "tl": 15
    },
    {
      "s": "You will receive the best possible care whether you continue to take part or not.",
      "t": "不论患者是否参加，都将获得最佳的护理。",
      "c": 0.94,
      "m": "Assurance of quality care regardless of participation",
      "sl": 15,
      "tl": 15
    },
    {
      "s": "If you decide that you want to continue to take part in the research project, you will be asked to sign the consent section.",
      "t": "如果您决定让患者参加本研究项目，您将需要签署同意书部分。",
      "c": 0.93,
      "m": "Consent signing requirement",
      "sl": 16,
      "tl": 16
    },
    {
      "s": "By signing it you are telling us that you:",
      "t": "签署同意书即表示您：",
      "c": 0.95,
      "m": "Introduction to consent implications",
      "sl": 16,
      "tl": 16
    },
    {
      "s": "understand what you have read;",
      "t": "理解您所阅读的内容；",
      "c": 0.96,
      "m": "Consent element - understanding",
      "sl": 17,
      "tl": 17
    },
    {
      "s": "consent to continuing in the research project;",
      "t": "同意患者参加本研究项目；",
      "c": 0.95,
      "m": "Consent element - participation",
      "sl": 18,
      "tl": 18
    },
    {
      "s": "consent to continuing to have the tests and treatments that are described;",
      "t": "同意患者接受所描述的测试和治疗；",
      "c": 0.94,
      "m": "Consent element - tests and treatments",
      "sl": 19,
      "tl": 19
    },
    {
      "s": "consent to the use of your personal and health information as described.",
      "t": "同意让有关方面依据本文件所述的方式使用患者的个人和健康资料。",
      "c": 0.93,
      "m": "Consent element - information use",
      "sl": 20,
      "tl": 20
    },
    {
      "s": "You will be given a copy of this Participant Information and Consent Form (Consent to Continue) to keep.",
      "t": "您将接获一份本《患者信息及同意书（合法代表）》的副本，以供保存。",
      "c": 0.92,
      "m": "Copy provision statement",
      "sl": 21,
      "tl": 21
    },
    {
      "s": "What is the purpose of this research?",
      "t": "本研究的目的是什么？",
      "c": 0.97,
      "m": "Section heading",
      "sl": 22,
      "tl": 22
    },
    {
      "s": "Traumatic brain injury (TBI) is usually caused by a blow to the head such as in a car accident or in a fall.",
      "t": "创伤性脑损伤（TBI）通常由头部受击（例如在交通事故或跌倒时）引起。",
      "c": 0.96,
      "m": "TBI causes explanation",
      "sl": 23,
      "tl": 23
    },
    {
      "s": "Many people who have a TBI do not survive or, if they do, suffer from long-term disability.",
      "t": "许多遭受 TBI 的人无法存活，即便幸存下来，也会导致长期残疾。",
      "c": 0.95,
      "m": "TBI outcomes description",
      "sl": 23,
      "tl": 23
    },
    {
      "s": "Previous studies have shown that about 1,000 people in Australia and New Zealand suffer a moderate or severe TBI every year.",
      "t": "以往的研究表明，澳洲和纽西兰每年约有 1,000人 罹患中度或重度 TBI。",
      "c": 0.96,
      "m": "TBI incidence statistics",
      "sl": 23,
      "tl": 23
    },
    {
      "s": "With current best available treatment and therapies many of these patients have loss of brain function.",
      "t": "即使采用目前最好的治疗和疗法，许多此类患者仍会丧失脑功能。",
      "c": 0.94,
      "m": "Current treatment limitations",
      "sl": 23,
      "tl": 23
    },
    {
      "s": "This can result in varying degrees of long term disability.",
      "t": "这可能导致不同程度的长期残疾。",
      "c": 0.96,
      "m": "Long-term disability consequence",
      "sl": 23,
      "tl": 23
    },
    {
      "s": "When a patient sustains a traumatic brain injury there are two stages to the injury.",
      "t": "当患者遭受创伤性脑损伤时，损伤会经历两个阶段。",
      "c": 0.95,
      "m": "Two-stage injury explanation",
      "sl": 24,
      "tl": 24
    },
    {
      "s": "The initial impact to the head causes immediate damage to the brain.",
      "t": "最初的头部撞击会造成脑部立即受损。",
      "c": 0.96,
      "m": "Primary injury description",
      "sl": 24,
      "tl": 24
    },
    {
      "s": "The second stage is the secondary injury phase, and it can evolve over hours or weeks.",
      "t": "第二阶段为继发性损伤阶段，可能在数小时或数周内发生。",
      "c": 0.94,
      "m": "Secondary injury timing",
      "sl": 24,
      "tl": 24
    },
    {
      "s": "This stage can cause more damage to the brain.",
      "t": "此阶段可能造成脑部进一步受损。",
      "c": 0.96,
      "m": "Secondary injury impact",
      "sl": 24,
      "tl": 24
    },
    {
      "s": "The treatment of brain injury focuses on trying to minimize the secondary injury and there is much research being done to try to find treatments that will prevent it.",
      "t": "脑损伤的治疗侧重于试图尽可能地减少继发性损伤，大量正在进行的研究都希望找到预防继发性损伤的疗法。",
      "c": 0.93,
      "m": "Treatment focus and research context",
      "sl": 24,
      "tl": 24
    },
    {
      "s": "Erythropoietin (EPO) has recently been recognised as a drug that may offer some protection to the brain injured by trauma and help reduce the effects of secondary injury.",
      "t": "促红细胞生成素（EPO）最近被确认为一种可能给受创伤的脑部提供某种保护的药物，并有助于减少继发性损伤的影响。",
      "c": 0.94,
      "m": "EPO potential benefits description",
      "sl": 25,
      "tl": 25
    },
    {
      "s": "A randomised controlled trial means that the study treatment is allocated randomly (by chance, like flipping a coin).",
      "t": "随机化对照试验表示研究疗法将被随机（如同抛硬币般具有偶然性）分配。",
      "c": 0.95,
      "m": "Randomized trial definition",
      "sl": 29,
      "tl": 29
    },
    {
      "s": "A computer will be used to allocate the patient to one of the two treatments so study staff cannot influence or predict this process.",
      "t": "试验将使用电脑为患者分配两种疗法中的一种，这样研究人员就无法影响或预测此过程。",
      "c": 0.96,
      "m": "Computer allocation explanation",
      "sl": 29,
      "tl": 29
    },
    {
      "s": "This study is funded by the Australian and Victorian Governments and has been designed by investigators from the Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS CTG).",
      "t": "本研究由澳洲和维多利亚州政府资助，并由来自澳洲和纽西兰重症监护学会临床试验组（ANZICS CTG）的研究员设计。",
      "c": 0.95,
      "m": "Study funding and design",
      "sl": 30,
      "tl": 30
    },
    {
      "s": "The study is managed by the Australian and New Zealand Intensive Care Research Centre (ANZIC-RC) at Monash University.",
      "t": "本研究由莫纳什大学的澳洲和纽西兰重症监护研究中心（ANZIC-RC）管理。",
      "c": 0.96,
      "m": "Study management",
      "sl": 30,
      "tl": 30
    },
    {
      "s": "The study will be conducted at hospitals in Australia, New Zealand, Singapore, France and Finland and will enrol 606 patients over 3.5 years.",
      "t": "本研究将在澳洲、纽西兰、新加坡、法国及芬兰的医院展开，并将在三年半期间招募 606 名患者。",
      "c": 0.96,
      "m": "Study locations and enrollment",
      "sl": 31,
      "tl": 31
    },
    {
      "s": "In Singapore, we plan to enrol approximately 30 patients at National Neuroscience Institute / Tan Tock Seng Hospital over a period of 3 years.",
      "t": "在新加坡，我们计划在3年的时间里在国立脑神经医学院/ 陈笃生医院招募大约 30 名患者。",
      "c": 0.97,
      "m": "Singapore-specific enrollment plan",
      "sl": 31,
      "tl": 31
    },
    {
      "s": "What does participation in this research involve?",
      "t": "参加本研究涉及哪些事项？",
      "c": 0.96,
      "m": "Section heading",
      "sl": 32,
      "tl": 32
    },
    {
      "s": "You were eligible for the study because you received a moderate or severe traumatic head injury.",
      "t": "因为患者受到过中度或重度创伤性头部损伤，所以有资格参加本研究。",
      "c": 0.95,
      "m": "Eligibility criteria",
      "sl": 33,
      "tl": 33
    },
    {
      "s": "If you are a woman of child bearing potential a blood sample (10 mls or 2 teaspoons) was collected to see if you are pregnant if test had not already been performed.",
      "t": "如果患者是具有生育能力的女性，则将采集血样（10 毫升或 2 茶匙）来查看其是否怀孕（若尚未接受过检查）。",
      "c": 0.94,
      "m": "Pregnancy testing procedure",
      "sl": 34,
      "tl": 34
    },
    {
      "s": "You were randomly allocated by a computer to receive a subcutaneous (SC) injection (a small injection under the skin) of either:",
      "t": "如果您同意患者参加，患者将由电脑随机分配，在脑损伤发生之后的 24 小时内以皮下（SC）注射（将小剂量药液注入皮肤下）的方式接获：",
      "c": 0.92,
      "m": "Random allocation and injection method",
      "sl": 35,
      "tl": 35
    },
    {
      "s": "EPO 40,000 units (1 ml in volume)",
      "t": "EPO 40,000 个单位（1 毫升容量）",
      "c": 0.98,
      "m": "EPO dosage specification",
      "sl": 36,
      "tl": 36
    },
    {
      "s": "or",
      "t": "或",
      "c": 1.0,
      "m": "Alternative option",
      "sl": 37,
      "tl": 37
    },
    {
      "s": "placebo (sodium chloride 0.9% (salty water)1 ml in volume)",
      "t": "安慰剂（0.9% 的氯化钠（盐水）1 毫升容量）",
      "c": 0.97,
      "m": "Placebo specification",
      "sl": 38,
      "tl": 38
    },
    {
      "s": "within 24 hrs after the brain injury has occurred.",
      "t": "随机化意味着患者将被偶然（如同抛硬币或掷骰子般）分配到两组中的一组。",
      "c": 0.8,
      "m": "Timing requirement - note target restructured this information",
      "sl": 39,
      "tl": 39
    },
    {
      "s": "Randomization means assigning you to one of the two groups by chance, like tossing a coin or rolling dice.",
      "t": "在脑损伤发生之后的 24 小时内",
      "c": 0.8,
      "m": "Randomization definition - note target restructured this information",
      "sl": 39,
      "tl": 39
    },
    {
      "s": "No additional blood samples were collected specifically for the study.",
      "t": "本研究将不会专门采集额外的血样。",
      "c": 0.96,
      "m": "Blood sample collection policy",
      "sl": 41,
      "tl": 41
    },
    {
      "s": "Results from blood samples collected as part of routine daily care while you were in the ICU were recorded.",
      "t": "不过在患者入住 ICU 期间，作为日常护理的一部分所采集的血样结果将被记录。",
      "c": 0.94,
      "m": "Routine blood sample usage",
      "sl": 41,
      "tl": 41
    },
    {
      "s": "You were closely monitored for blood clots in the legs.",
      "t": "研究人员将密切监测患者的腿部是否出现血凝块。",
      "c": 0.95,
      "m": "Clot monitoring statement",
      "sl": 42,
      "tl": 42
    },
    {
      "s": "Treatments to prevent blood clots from occurring were started as soon as possible after ICU admission.",
      "t": "住进 ICU 之后将尽快开始预防出现血凝块的治疗。",
      "c": 0.95,
      "m": "Preventive treatment timing",
      "sl": 42,
      "tl": 42
    },
    {
      "s": "An ultrasound scan of the upper legs was done before or at least within 48 hours after the first dose of study drug was given.",
      "t": "在接获第一剂研究药物之前或在之后的至少 48 小时内，将进行大腿超声波扫描。",
      "c": 0.94,
      "m": "Ultrasound timing requirement",
      "sl": 42,
      "tl": 42
    },
    {
      "s": "The ultrasound was done twice a week whilst you were in the ICU so that if any blood clots developed they were detected early and treated immediately.",
      "t": "在患者入住 ICU 期间，一周将进行两次超声波扫描，以便尽早发现和及时治疗出现的血凝块。",
      "c": 0.95,
      "m": "Ultrasound frequency and purpose",
      "sl": 42,
      "tl": 42
    },
    {
      "s": "The ultrasound is a test that is done at the bedside where a small flat scanner (like a computer mouse) is placed on the thigh.",
      "t": "超声波扫描是将一台小型平板扫描仪（如同电脑鼠标）放在大腿上，在床边进行的一种检查。",
      "c": 0.96,
      "m": "Ultrasound procedure description",
      "sl": 42,
      "tl": 42
    },
    {
      "s": "A sticky gel is used to assist the scanner to see the leg veins on a computer screen.",
      "t": "检查时会使用粘性凝胶，协助扫描者在电脑屏幕上观察腿部静脉。",
      "c": 0.95,
      "m": "Ultrasound gel usage",
      "sl": 42,
      "tl": 42
    },
    {
      "s": "You would only receive study drug once a week, for up to 3 doses and the scheduled leg ultrasounds (up to 7 scans) while you were in the ICU.",
      "t": "在患者入住 ICU 期间，一周将只会接获一次研究药物（最多 3 剂）和预定的腿部超声波扫描（最多 7 次）。",
      "c": 0.94,
      "m": "Treatment and monitoring schedule",
      "sl": 43,
      "tl": 43
    },
    {
      "s": "To complete the entire schedule takes 21 days.",
      "t": "完成整个研究计划将需要 21 天的时间。",
      "c": 0.96,
      "m": "Full schedule duration",
      "sl": 43,
      "tl": 43
    },
    {
      "s": "If you were well enough to be discharged to the ward before 21 days, you did not receive the total schedule of study drug or ultrasounds.",
      "t": "如果患者的健康状况允许其在 21 天之前转到普通病房，则患者便无需接获整个研究计划规定的研究药物或超声波扫描。",
      "c": 0.95,
      "m": "Early discharge implications",
      "sl": 43,
      "tl": 43
    },
    {
      "s": "The ICU doctor monitored you for any signs of blood clots, which is part of standard care of the TBI patient.",
      "t": "作为 TBI 患者标准护理的一部分，ICU 医生将监测患者是否有任何血凝块形成的征兆。",
      "c": 0.94,
      "m": "Standard care monitoring",
      "sl": 43,
      "tl": 43
    },
    {
      "s": "Information about your injury and management during your hospital stay will be collected from your medical record.",
      "t": "有关患者在住院期间的损伤和管理的信息，将从其医疗记录中进行收集。",
      "c": 0.95,
      "m": "Data collection from medical records",
      "sl": 44,
      "tl": 44
    },
    {
      "s": "Follow up",
      "t": "跟进",
      "c": 0.95,
      "m": "Section heading",
      "sl": 45,
      "tl": 45
    },
    {
      "s": "A follow up phone interview will be conducted 6 months after the injury by a research member from the hospital to find out how well you have recovered from the brain injury.",
      "t": "来自医院的研究人员将在损伤之后的 6 个月后对患者进行电话跟进，以便了解患者从脑损伤事故中康复的情况。",
      "c": 0.94,
      "m": "Follow-up interview description",
      "sl": 46,
      "tl": 46
    },
    {
      "s": "A discussion may also be held with your relative and the rehabilitation staff involved with your care to help us assess recovery.",
      "t": "研究人员还可能与您和参与患者护理的康复工作人员进行讨论，以帮助我们评估康复情况。",
      "c": 0.93,
      "m": "Additional assessment methods",
      "sl": 46,
      "tl": 46
    },
    {
      "s": "The phone interview will take 30 minutes to complete.",
      "t": "电话访谈需要 30 分钟的时间。",
      "c": 0.97,
      "m": "Interview duration",
      "sl": 46,
      "tl": 46
    },
    {
      "s": "Once you are entered into the study, your contact details will be released to the research member conducting the interview.",
      "t": "一旦患者参加研究，您的联络资料就会被披露给进行访谈的研究人员。",
      "c": 0.95,
      "m": "Contact information sharing",
      "sl": 47,
      "tl": 47
    },
    {
      "s": "You will receive a phone call shortly before 6 months from research staff looking after you who will arrange a convenient time for the phone interview.",
      "t": "护理患者的研究人员将在接近 6 个月时打电话联络您，以便安排合适的时间进行电话访谈。",
      "c": 0.94,
      "m": "Interview scheduling process",
      "sl": 47,
      "tl": 47
    },
    {
      "s": "You will not be paid for your participation in this research.",
      "t": "患者不会因参加本研究而获得任何报酬。",
      "c": 0.96,
      "m": "No compensation statement",
      "sl": 48,
      "tl": 48
    },
    {
      "s": "Kidney function monitoring",
      "t": "肾功能监测",
      "c": 0.97,
      "m": "Section heading",
      "sl": 49,
      "tl": 49
    },
    {
      "s": "ICU patients with TBI can be at risk of developing kidney damage.",
      "t": "患有 TBI 的 ICU 患者可能会有出现肾功能损害的风险。",
      "c": 0.96,
      "m": "Kidney damage risk",
      "sl": 50,
      "tl": 50
    },
    {
      "s": "Kidney damage increases the risk of brain swelling which may slow recovery of the brain and increase hospital stay.",
      "t": "肾功能损害会增加脑肿胀的风险，这可能会减缓脑部的康复并延长住院时间。",
      "c": 0.95,
      "m": "Kidney damage consequences",
      "sl": 50,
      "tl": 50
    },
    {
      "s": "EPO has been shown in many experimental studies to protect the kidneys from damage.",
      "t": "许多实验性研究表明，EPO 能够保护肾脏免受损害。",
      "c": 0.96,
      "m": "EPO kidney protection evidence",
      "sl": 50,
      "tl": 50
    },
    {
      "s": "In addition to the protective effects on the brain, EPO has also been shown to protect the kidneys damaged after an injury.",
      "t": "除了对脑部的保护作用，EPO 还被证实能够在损伤之后保护受损的肾脏。",
      "c": 0.95,
      "m": "EPO dual protection benefits",
      "sl": 50,
      "tl": 50
    },
    {
      "s": "Kidney function is monitored by collecting information about urine output and blood test results.",
      "t": "患者的肾功能将通过收集有关尿量和验血结果的信息进行监测。",
      "c": 0.96,
      "m": "Kidney monitoring methods",
      "sl": 50,
      "tl": 50
    },
    {
      "s": "This is part of standard care in the ICU.",
      "t": "这是 ICU 标准护理的一部分。",
      "c": 0.98,
      "m": "Standard care context",
      "sl": 50,
      "tl": 50
    },
    {
      "s": "What are the possible benefits?",
      "t": "可能获得什么益处？",
      "c": 0.96,
      "m": "Section heading",
      "sl": 51,
      "tl": 51
    },
    {
      "s": "You may not receive any benefits from this research but possible benefits may include a better recovery and quality of life for future patients with moderate or severe TBI.",
      "t": "患者可能不会从本研究中受益，但对于未来罹患中度或重度 TBI 的患者而言，可能获得的益处则包括更好地康复和更高的生活素质。",
      "c": 0.94,
      "m": "Potential benefits description",
      "sl": 52,
      "tl": 52
    },
    {
      "s": "What are the possible risks?",
      "t": "可能的风险有哪些？",
      "c": 0.96,
      "m": "Section heading",
      "sl": 54,
      "tl": 53
    },
    {
      "s": "Medical treatments sometimes cause side effects.",
      "t": "医学治疗有时会引起副作用。",
      "c": 0.97,
      "m": "Side effects introduction",
      "sl": 55,
      "tl": 54
    },
    {
      "s": "You may have none, some or all of the effects listed below, and they may be mild, moderate or severe.",
      "t": "患者可能不会出现、也可能会出现下列部分或全部的副作用，而这些副作用可能为轻度、中度或重度。",
      "c": 0.95,
      "m": "Side effect variability",
      "sl": 55,
      "tl": 54
    },
    {
      "s": "The ICU doctors closely monitored you for any side effects.",
      "t": "ICU 的医生将密切监测患者是否出现任何副作用。",
      "c": 0.96,
      "m": "Side effect monitoring",
      "sl": 55,
      "tl": 54
    },
    {
      "s": "If you develop any of these side effects, the doctor will let you know.",
      "t": "如果患者出现这些副作用中的任何一种，医生会告诉您。",
      "c": 0.96,
      "m": "Side effect communication",
      "sl": 55,
      "tl": 54
    },
    {
      "s": "Many side effects go away shortly after treatment ends.",
      "t": "许多副作用在治疗结束后不久就会消失。",
      "c": 0.97,
      "m": "Side effect duration - temporary",
      "sl": 56,
      "tl": 55
    },
    {
      "s": "However, sometimes side effects can be serious, long lasting or permanent.",
      "t": "不过，有时副作用可能是严重、持久性或永久性的。",
      "c": 0.96,
      "m": "Side effect duration - persistent",
      "sl": 56,
      "tl": 55
    },
    {
      "s": "If a severe side effect or reaction occurred, the ICU doctor may have stopped the study drug.",
      "t": "如果出现严重的副作用或不良反应，ICU 的医生可能需要停用研究药物。",
      "c": 0.95,
      "m": "Severe side effect management",
      "sl": 56,
      "tl": 55
    },
    {
      "s": "The ICU doctor would have discussed the best way of managing any side effects with your next of kin.",
      "t": "ICU 的医生将与您和患者讨论管理副作用的最佳方式。",
      "c": 0.93,
      "m": "Side effect management discussion",
      "sl": 56,
      "tl": 55
    },
    {
      "s": "The side effects of EPO related to the dose given include: a temporary increase in blood pressure that returns to normal when EPO is discontinued, diarrhoea, nausea, vomiting, headache and flu-like symptoms.",
      "t": "接获相应剂量 EPO 可能产生的副作用包括：血压暂时升高（停用 EPO 后即可恢复正常）、腹泻、恶心、呕吐、头疼及类似流感的症状。",
      "c": 0.94,
      "m": "EPO-specific side effects",
      "sl": 57,
      "tl": 56
    },
    {
      "s": "In patients with other conditions these events occurred in less than 5% of patients.",
      "t": "在患有其他疾病的患者中，这些副作用的发生率低于5%。",
      "c": 0.95,
      "m": "Side effect incidence rate",
      "sl": 57,
      "tl": 56
    },
    {
      "s": "This is similar to patients who received placebo.",
      "t": "这个数值与接获安慰剂的患者类似。",
      "c": 0.97,
      "m": "Placebo comparison",
      "sl": 57,
      "tl": 56
    },
    {
      "s": "All patients in ICU have an increased risk (approx. 10%) of developing clots in the blood vessels (called thrombosis or embolism).",
      "t": "所有 ICU 的患者出现血管内凝块（称为血栓形成或栓塞）的风险均会增加（大约为 10%），",
      "c": 0.95,
      "m": "General clot risk in ICU",
      "sl": 58,
      "tl": 57
    },
    {
      "s": "EPO may pose an additional risk for developing clots.",
      "t": "而 EPO 可能会造成出现凝块的额外风险。",
      "c": 0.96,
      "m": "EPO additional clot risk",
      "sl": 58,
      "tl": 57
    },
    {
      "s": "A recent study revealed 8.7% of patients receiving EPO developed a clot in the legs compared to 5.8% of patients who received the placebo injection.",
      "t": "最近的一项研究显示，与接获安慰剂注射的患者相比（5.8％），接获 EPO 的患者中有 8.7％ 出现腿部凝块。",
      "c": 0.96,
      "m": "Clot incidence comparison",
      "sl": 58,
      "tl": 57
    },
    {
      "s": "Although it is extremely rare, EPO may also cause fits (less than 1%), chronic anaemia (very rare), arterial thrombosis and heart attack.",
      "t": "尽管以下情况极为罕见，但 EPO 还有可能引起抽搐（不到 1％）、慢性贫血（非常罕见）、动脉血栓形成及心脏病发作。",
      "c": 0.95,
      "m": "Rare EPO side effects",
      "sl": 58,
      "tl": 57
    },
    {
      "s": "It is for these reasons that frequent ultrasounds of the upper legs have been scheduled so the formation of blood clot can be detected early.",
      "t": "正是由于这些原因，才安排了频繁的大腿超声波扫描，以便及早发现血凝块的形成。",
      "c": 0.96,
      "m": "Ultrasound rationale",
      "sl": 58,
      "tl": 57
    },
    {
      "s": "As part of routine care of the ICU patient, continuous monitoring of the heart rhythm and blood pressure is performed.",
      "t": "作为 ICU 患者常规护理的一部分，会对心律和血压进行连续监测。",
      "c": 0.96,
      "m": "Routine cardiac monitoring",
      "sl": 58,
      "tl": 57
    },
    {
      "s": "This allows clinical staff to monitor these heart functions continuously for any changes.",
      "t": "这使得临床医护人员能够持续不断地监测这些心脏功能是否出现任何变化。",
      "c": 0.96,
      "m": "Monitoring purpose",
      "sl": 58,
      "tl": 57
    },
    {
      "s": "Allergic reactions to EPO are rare.",
      "t": "对 EPO 过敏的反应比较罕见，",
      "c": 0.97,
      "m": "Allergy rarity statement",
      "sl": 59,
      "tl": 58
    },
    {
      "s": "They include rash, itching, anaphylactic reaction (allergic shock) and accumulation of fluid around the eyes.",
      "t": "包括皮疹、瘙痒、过敏性反应（过敏性休克）及眼周积液。",
      "c": 0.96,
      "m": "Allergy symptoms",
      "sl": 59,
      "tl": 58
    },
    {
      "s": "Having an injection may cause some discomfort or bruising (0.2% of patients) and should resolve quickly with minimal treatment.",
      "t": "注射可能会造成某些不适或瘀伤（0.2％ 的患者），应迅速采用最低限度的治疗来予以消除。",
      "c": 0.95,
      "m": "Injection site reactions",
      "sl": 60,
      "tl": 59
    },
    {
      "s": "Alternative treatment",
      "t": "替代疗法",
      "c": 0.97,
      "m": "Section heading",
      "sl": 61,
      "tl": 60
    },
    {
      "s": "If you choose not to take part in this study, the alternative is to have what is considered standard care for your condition.",
      "t": "如果您选择不让患者参加本研究，另一种选择是考虑采用标准护理来治疗患者的疾病。",
      "c": 0.95,
      "m": "Alternative treatment option",
      "sl": 62,
      "tl": 61
    },
    {
      "s": "The doctor-in-charge will decide on what other drugs and therapies may be available to treat your traumatic brain injury.",
      "t": "主治医师将决定哪些其他药物和疗法可用于治疗患者的创伤性脑损伤。",
      "c": 0.96,
      "m": "Treatment decision authority",
      "sl": 62,
      "tl": 61
    },
    {
      "s": "What is not standard care or experimental in this study?",
      "t": "本研究中哪些属于非标准护理或具有实验性？",
      "c": 0.95,
      "m": "Section heading",
      "sl": 63,
      "tl": 62
    },
    {
      "s": "The administration of the study drug EPO and the ultrasound scans are the only procedures that are non-standard.",
      "t": "研究药物 EPO 的给药是非标准程序，",
      "c": 0.94,
      "m": "Non-standard procedures",
      "sl": 64,
      "tl": 63
    },
    {
      "s": "Every other procedure is current standard of care.",
      "t": "其他各程序均为目前的标准护理。",
      "c": 0.97,
      "m": "Standard procedures",
      "sl": 64,
      "tl": 63
    },
    {
      "s": "All the procedures performed in this study are the procedures of routine care in National Neuroscience Institute and Tan Tock Seng Hospital.",
      "t": "本研究中所执行的全部程序均为国立脑神经医学院和陈笃生医院的常规护理程序，",
      "c": 0.96,
      "m": "Routine care context",
      "sl": 65,
      "tl": 64
    },
    {
      "s": "They are not performed solely for the purposes of this study but to ensure that patients receive excellent treatment.",
      "t": "其执行不仅是为了本研究的目的，也是为了确保患者获得最佳的治疗。",
      "c": 0.95,
      "m": "Dual purpose of procedures",
      "sl": 65,
      "tl": 64
    },
    {
      "s": "What if I am taking placebo instead of EPO?",
      "t": "如果患者接获的是安慰剂而不是 EPO，怎么办？",
      "c": 0.96,
      "m": "Section heading",
      "sl": 66,
      "tl": 65
    },
    {
      "s": "Receiving placebo is the same as not having any additional treatment except for the standard medical care which you will continue to receive during the study.",
      "t": "接获安慰剂等同于，除标准医疗护理（研究期间患者将继续接受）以外不接受任何额外治疗。",
      "c": 0.95,
      "m": "Placebo equivalence explanation",
      "sl": 67,
      "tl": 66
    },
    {
      "s": "Costs of participation",
      "t": "参加的费用",
      "c": 0.97,
      "m": "Section heading",
      "sl": 68,
      "tl": 67
    },
    {
      "s": "The patient does not need to pay for the placebo or the EPO study drug or any study related procedures.",
      "t": "患者无需为安慰剂或 EPO 研究药物或任何研究相关的程序支付费用。",
      "c": 0.96,
      "m": "Study-related cost coverage",
      "sl": 69,
      "tl": 68
    },
    {
      "s": "However, any standard medical care will be charged to you during the research study.",
      "t": "不过，患者需要承担研究期间的标准医疗护理费用。",
      "c": 0.96,
      "m": "Standard care costs responsibility",
      "sl": 69,
      "tl": 68
    },
    {
      "s": "What if new information arises during this research project?",
      "t": "如果在本研究项目期间出现新信息，怎么办？",
      "c": 0.96,
      "m": "Section heading",
      "sl": 70,
      "tl": 69
    },
    {
      "s": "During the research project, new information about the risks and benefits of the project may become known to the researchers.",
      "t": "在研究期间，研究人员可能会获悉与项目的风险和益处有关的新信息。",
      "c": 0.95,
      "m": "New information possibility",
      "sl": 71,
      "tl": 70
    },
    {
      "s": "If this occurs, you will be told about this new information and the doctor will discuss whether this new information affects you.",
      "t": "如果出现这种情况，您将获知此类新信息，而且医生将探讨新信息是否会对患者产生影响。",
      "c": 0.94,
      "m": "New information communication process",
      "sl": 71,
      "tl": 70
    },
    {
      "s": "Can you have other treatments during this research project?",
      "t": "患者是否能在本研究项目期间接受其他的治疗？",
      "c": 0.95,
      "m": "Section heading",
      "sl": 72,
      "tl": 71
    },
    {
      "s": "It is important to tell the doctor and the research staff about any treatments or medications you may be taking, including over-the-counter medications, vitamins or herbal remedies, acupuncture or other alternative treatments.",
      "t": "重要的是，请务必将患者可能正在接受的任何治疗或正在服用的任何药物告知医生和研究人员，包括非处方药物、维生素或草药、针灸或其他替代疗法。",
      "c": 0.94,
      "m": "Treatment disclosure requirement",
      "sl": 73,
      "tl": 72
    },
    {
      "s": "You should also tell the doctor about any changes to these during your participation in the research.",
      "t": "您还应将上述情况在患者参加研究期间的变化告知医生。",
      "c": 0.96,
      "m": "Treatment change notification",
      "sl": 73,
      "tl": 72
    },
    {
      "s": "Do I have to take part in this research project?",
      "t": "患者必须参加此研究项目吗？",
      "c": 0.96,
      "m": "Section heading",
      "sl": 74,
      "tl": 73
    },
    {
      "s": "Participation in any research project is voluntary.",
      "t": "任何研究项目均为自愿参加。",
      "c": 0.98,
      "m": "Voluntary participation principle",
      "sl": 75,
      "tl": 74
    },
    {
      "s": "If you decide that you would not wish to take part in this study, you may request to be withdrawn from the study.",
      "t": "如果您决定患者不希望参加本研究，您可以要求让患者退出研究。",
      "c": 0.95,
      "m": "Withdrawal right",
      "sl": 75,
      "tl": 74
    },
    {
      "s": "If you consent to continue and then later change your mind, you can withdraw from the study at any time.",
      "t": "如果您同意后又改变主意，您仍然可以随时让患者退出研究。",
      "c": 0.95,
      "m": "Withdrawal timing flexibility",
      "sl": 75,
      "tl": 74
    },
    {
      "s": "Any decision you make will not affect either your relationship with National Neuroscience Institute / Tan Tock Seng Hospital.",
      "t": "您所作出的任何决定都不会影响您或患者与国立脑神经医学院/陈笃生医院的关系。",
      "c": 0.96,
      "m": "No relationship impact assurance",
      "sl": 76,
      "tl": 75
    },
    {
      "s": "Withdrawing from the study will not affect your care in anyway and you will continue to receive the best current treatment and care.",
      "t": "退出研究并不会在任何方面影响患者的护理，而且患者将继续获得目前最佳的治疗和护理。",
      "c": 0.95,
      "m": "No care impact assurance",
      "sl": 76,
      "tl": 75
    },
    {
      "s": "If you do decide to withdraw the researchers would like to keep the information that has been collected so far.",
      "t": "如果您决定让患者退出，研究人员会希望保存截至目前为止所收集的信息。",
      "c": 0.96,
      "m": "Data retention request",
      "sl": 77,
      "tl": 76
    },
    {
      "s": "This is to help them make sure that the results of the research can be measured properly.",
      "t": "这是为了帮助他们确保研究的结果能够得到正确的测量。",
      "c": 0.96,
      "m": "Data retention purpose",
      "sl": 77,
      "tl": 76
    },
    {
      "s": "Please tell the researcher if you do not want them to do this.",
      "t": "如果您不希望研究人员这么做，请告知他们。",
      "c": 0.97,
      "m": "Data retention opt-out",
      "sl": 77,
      "tl": 76
    },
    {
      "s": "Could this research project be stopped unexpectedly?",
      "t": "本研究项目会意外中止吗？",
      "c": 0.96,
      "m": "Section heading",
      "sl": 78,
      "tl": 78
    },
    {
      "s": "This research project may be stopped for a variety of reasons including:",
      "t": "本研究项目可能因各种原因而中止，包括：",
      "c": 0.97,
      "m": "Study termination possibility",
      "sl": 79,
      "tl": 79
    },
    {
      "s": "Unacceptable side effects;",
      "t": "无法接受的副作用；",
      "c": 0.98,
      "m": "Termination reason - side effects",
      "sl": 80,
      "tl": 80
    },
    {
      "s": "The drug/treatment being shown not to be effective; and",
      "t": "药物/疗法经证实无效；以及",
      "c": 0.97,
      "m": "Termination reason - ineffectiveness",
      "sl": 81,
      "tl": 81
    },
    {
      "s": "The drug/treatment being shown to work and not need further testing.",
      "t": "药物/疗法经证实有效而无需进一步试验。",
      "c": 0.96,
      "m": "Termination reason - proven effectiveness",
      "sl": 82,
      "tl": 82
    },
    {
      "s": "How will I be informed of the results of this research project?",
      "t": "我将如何获悉本研究项目的结果？",
      "c": 0.96,
      "m": "Section heading",
      "sl": 83,
      "tl": 83
    },
    {
      "s": "Once the project has been completed, a summary of the results will be available from the investigator on request.",
      "t": "一旦项目完成，研究员即可根据要求提供结果摘要。",
      "c": 0.96,
      "m": "Results availability",
      "sl": 84,
      "tl": 84
    },
    {
      "s": "What will happen to information about me?",
      "t": "有关患者的信息将如何处理？",
      "c": 0.96,
      "m": "Section heading",
      "sl": 85,
      "tl": 85
    },
    {
      "s": "The information gathered about you by the researchers or obtained during the trial from any procedures, will be held by the researchers in strict confidence.",
      "t": "研究人员所收集或在试验期间从任何程序中所获得的有关患者的信息，将由研究人员以严格保密的方式进行保存。",
      "c": 0.95,
      "m": "Information confidentiality assurance",
      "sl": 86,
      "tl": 86
    },
    {
      "s": "Your trial records without your name attached will be made available to the Coordinating Centre at the ANZIC–RC, at Monash University in Australia.",
      "t": "患者的试验记录（不会出现其姓名）将提供给澳洲莫纳什大学 ANZIC–RC 的协调中心。",
      "c": 0.96,
      "m": "Anonymous data sharing",
      "sl": 86,
      "tl": 86
    },
    {
      "s": "All the people who handle your information will adhere to traditional standards of confidentiality and will also comply with all relevant privacy legislation in your country.",
      "t": "处理患者信息的所有人员均将恪守传统的保密标准，并将遵守您所在国家的所有相关隐私权法令。",
      "c": 0.95,
      "m": "Privacy compliance assurance",
      "sl": 86,
      "tl": 86
    },
    {
      "s": "In Australia this is the Privacy Act 1988.",
      "t": "在澳洲，此为《1988 年隐私权法令》。",
      "c": 0.98,
      "m": "Specific privacy law reference",
      "sl": 86,
      "tl": 86
    },
    {
      "s": "The Ethics Committee has obtained assurances from ANZIC-RC that the 'Information Privacy Principles' laid down in the Act will be met, and will oblige the investigator and other hospital staff to meet strict privacy standards.",
      "t": "ANZIC-RC 已向伦理委员会保证，将遵守此法令中所规定的\"信息隐私权原则\"，并将要求研究员及其他的医院工作人员遵守严格的隐私权标准。",
      "c": 0.94,
      "m": "Ethics committee assurances",
      "sl": 86,
      "tl": 86
    },
    {
      "s": "If the results of the trial are published in a medical journal, as is intended, no reader will be able to identify individual patients",
      "t": "如果试验的结果在医学期刊中发表（按照预定的意图），读者将无法识别个别的患者身份。",
      "c": 0.95,
      "m": "Publication anonymity assurance",
      "sl": 86,
      "tl": 86
    },
    {
      "s": "In any publication and/or presentation, information will be provided in such a way that cannot identify you, except with your permission.",
      "t": "在任何出版物和/或讲座中，信息都将以无法识别患者身份的方式提供，除非获得您的许可。",
      "c": 0.96,
      "m": "Presentation anonymity policy",
      "sl": 87,
      "tl": 87
    },
    {
      "s": "No identifying material will be used in any reports of this study.",
      "t": "任何可识别身份的资料均不会在本研究的任何报告中使用。",
      "c": 0.97,
      "m": "No identifying information policy",
      "sl": 87,
      "tl": 87
    },
    {
      "s": "Records for the study will be kept in a secure filing cabinet in a secure office.",
      "t": "研究的记录将保存在安全办公室的安全文件柜中。",
      "c": 0.97,
      "m": "Physical record storage",
      "sl": 88,
      "tl": 88
    },
    {
      "s": "A database with study information will be generated and this will be kept in a computer that is password protected.",
      "t": "所生成的研究信息数据库将存放在受到密码保护的电脑中。",
      "c": 0.96,
      "m": "Electronic record storage",
      "sl": 88,
      "tl": 88
    },
    {
      "s": "Records relating to the study will be kept for 15 years at this site.",
      "t": "与本研究相关的记录将在此地点保存 15 年。",
      "c": 0.98,
      "m": "Record retention period",
      "sl": 88,
      "tl": 88
    },
    {
      "s": "It is desirable that your local doctor is advised about your participation in this research project.",
      "t": "最好让患者当地的医生知道患者参加本研究项目之事。",
      "c": 0.96,
      "m": "Local doctor notification recommendation",
      "sl": 89,
      "tl": 89
    },
    {
      "s": "By signing the consent section, you agree to your local doctor being notified about participation in this research project.",
      "t": "签署同意书即表示，您同意让其当地的医生获知患者参加本研究项目之事。",
      "c": 0.95,
      "m": "Local doctor notification consent",
      "sl": 89,
      "tl": 89
    },
    {
      "s": "Information about participation in this research project may be recorded in your health records.",
      "t": "有关参加本研究项目的信息可能会记录在患者的病历中。",
      "c": 0.97,
      "m": "Health record documentation",
      "sl": 90,
      "tl": 90
    },
    {
      "s": "Regulatory Agencies (HSA, FDA, if relevant), Singhealth Centralised Institutional Review Board, NHG Domain-Specific Review Board and Ministry of Health will be granted direct access to your original medical records to check study procedures and data, without making any of your information public.",
      "t": "监管机构（HSA、FDA，如相关）、新加坡保健集团的Centralised Institutional Review Board 、NHG Domain-Specific Review Board 及卫生部将获准直接查阅患者的原始医疗记录，以便检查研究程序和数据，但不会公开其信息。",
      "c": 0.94,
      "m": "Regulatory access rights",
      "sl": 91,
      "tl": 91
    },
    {
      "s": "By signing the Informed Consent Form attached, you (or your legally acceptable representative, if relevant) are authorizing such access to your study and medical records.",
      "t": "签署所附的《知情同意书》即表示，您代表患者授予上述查阅其研究和医疗记录的权限。",
      "c": 0.93,
      "m": "Access authorization",
      "sl": 91,
      "tl": 91
    },
    {
      "s": "How can I access my information?",
      "t": "患者如何才能查阅其信息？",
      "c": 0.96,
      "m": "Section heading",
      "sl": 92,
      "tl": 92
    },
    {
      "s": "In accordance with relevant Australian and/or state privacy and other laws applicable in your country, you have the right to access the information collected and stored by the researchers about you.",
      "t": "根据相关的澳洲和/或州隐私权法及您所在国家适用的其他法律，患者有权查阅研究人员收集和储存的有关患者的信息。",
      "c": 0.94,
      "m": "Information access rights",
      "sl": 93,
      "tl": 93
    },
    {
      "s": "You also have the right to request that any information with which you disagree be corrected.",
      "t": "患者也有权要求更正其所不同意的任何信息。",
      "c": 0.96,
      "m": "Information correction rights",
      "sl": 93,
      "tl": 93
    },
    {
      "s": "Please contact a member of the study team listed in this document if you would like to access your information.",
      "t": "如果患者希望查阅自己的信息，请联络本文件中所列出的研究小组成员。",
      "c": 0.96,
      "m": "Contact information for access",
      "sl": 93,
      "tl": 93
    },
    {
      "s": "What happens if I am injured as a result of participating in this research project?",
      "t": "如果患者由于参加本研究项目而受伤，怎么办？",
      "c": 0.95,
      "m": "Section heading",
      "sl": 94,
      "tl": 94
    },
    {
      "s": "In the event that you suffer an adverse event or a medical accident during this study that arises from your participation in the study, you will be offered all full and necessary treatments by National Neuroscience Institute / Tan Tock Seng Hospital.",
      "t": "倘若患者因参加本研究而在本研究期间出现不良事件或医疗事故，国立脑神经医学院/陈笃生医院将为患者提供所有全面和必要的治疗。",
      "c": 0.94,
      "m": "Injury treatment assurance",
      "sl": 95,
      "tl": 95
    },
    {
      "s": "The Ethics Committee has approved this study on the basis (amongst others) that the reported risk of such an event is either small or acceptable in terms of the risk you face as a result of your current illness or the benefit that is possible with the new treatment being tested.",
      "t": "伦理委员会已批准本研究，依据是以患者因现有疾病而面临的风险或以试验中的新疗法的可能益处而言，（其中包括）所报告的此类事件之风险很小，或者是可以接受的。",
      "c": 0.92,
      "m": "Ethics approval rationale",
      "sl": 95,
      "tl": 95
    },
    {
      "s": "No provisions have been made in this trial to offer trial patients who suffer an adverse reaction monetary compensation, but the absence of such a provision does not remove your rights to seek compensation under common law.",
      "t": "本试验未作出为出现不良反应的试验患者提供金钱补偿的规定，但没有此类规定并不会剥夺您根据普通法要求补偿的权利。",
      "c": 0.93,
      "m": "Compensation policy",
      "sl": 95,
      "tl": 95
    },
    {
      "s": "Is this research project approved?",
      "t": "本研究项目获得批准了吗？",
      "c": 0.97,
      "m": "Section heading",
      "sl": 96,
      "tl": 96
    },
    {
      "s": "The ethical aspects of this research project have been approved by the Singhealth Centralised Institutional Review Board and NHG Domain Specific Review Board.",
      "t": "本研究项目的伦理方面已获得新加坡保健集团的 Centralised Institutional Review Board 和 NHG Domain-Specific Review Board 的批准。",
      "c": 0.97,
      "m": "Ethics approval statement",
      "sl": 97,
      "tl": 97
    }
  ]
}
```


ET0020_Mm Email - Primary.en-SG_id-ID.L1-T1

```json
{
  "combined_segments": [
    {
      "s": "You know that the negative implications for a poorly constructed pharmacovigilance framework and strategy is tremendous. The 4th Annual Pharmcovigilance Asia Summit is aimed at helping you to do your job better and faster. Download the summit brochure here.",
      "t": "Anda pasti tahu betapa besarnya implikasi negatif dari strategi dan kerangka kerja pharmacovigilance yang tidak disusun dengan baik. KTT Asia Tahunan Ke-4 mengenai Pharmacovigilance ditujukan untuk membantu Anda melakukan pekerjaan secara lebih baik dan lebih cepat. Unduh brosur KTT di sini.",
      "c": 0.95,
      "m": "Combined because these sentences form a coherent argument about consequences and the solution, with the call-to-action naturally following the problem statement",
      "sl": 9,
      "tl": 9
    },
    {
      "s": "P.S. Take advantage of our early bird offer! Save up to xxx when you book and pay before xxxxx! PPS Want to book in groups of 3 or more? Email us at enquiry@iqpc.com.sg to find out about group discounts available",
      "t": "N.B. Manfaatkan penawaran istimewa kami! Hemat hingga xxx jika Anda memesan dan membayar sebelum xxxxx! PPS Ingin memesan dalam grup beranggotakan 3 orang atau lebih? Kirimkan e-mail ke enquiry@iqpc.com.sg untuk mengetahui lebih lanjut tentang diskon khusus grup yang tersedia",
      "c": 0.9,
      "m": "Combined postscript sections as they are related promotional messages that function as a single unit in marketing communications",
      "sl": 18,
      "tl": 23
    }
  ],
  "combined_segments_split": [
    {
      "s": "You know that the negative implications for a poorly constructed pharmacovigilance framework and strategy is tremendous.",
      "t": "Anda pasti tahu betapa besarnya implikasi negatif dari strategi dan kerangka kerja pharmacovigilance yang tidak disusun dengan baik.",
      "c": 0.95,
      "m": "Split from combined segment - problem statement",
      "sl": 9,
      "tl": 9
    },
    {
      "s": "The 4th Annual Pharmcovigilance Asia Summit is aimed at helping you to do your job better and faster.",
      "t": "KTT Asia Tahunan Ke-4 mengenai Pharmacovigilance ditujukan untuk membantu Anda melakukan pekerjaan secara lebih baik dan lebih cepat.",
      "c": 0.95,
      "m": "Split from combined segment - solution presentation",
      "sl": 9,
      "tl": 9
    },
    {
      "s": "Download the summit brochure here.",
      "t": "Unduh brosur KTT di sini.",
      "c": 0.95,
      "m": "Split from combined segment - call to action",
      "sl": 9,
      "tl": 9
    },
    {
      "s": "P.S. Take advantage of our early bird offer! Save up to xxx when you book and pay before xxxxx!",
      "t": "N.B. Manfaatkan penawaran istimewa kami! Hemat hingga xxx jika Anda memesan dan membayar sebelum xxxxx!",
      "c": 0.9,
      "m": "Split from combined segment - early bird promotion",
      "sl": 18,
      "tl": 23
    },
    {
      "s": "PPS Want to book in groups of 3 or more? Email us at enquiry@iqpc.com.sg to find out about group discounts available",
      "t": "PPS Ingin memesan dalam grup beranggotakan 3 orang atau lebih? Kirimkan e-mail ke enquiry@iqpc.com.sg untuk mengetahui lebih lanjut tentang diskon khusus grup yang tersedia",
      "c": 0.9,
      "m": "Split from combined segment - group booking promotion",
      "sl": 18,
      "tl": 23
    }
  ],
  "sentence_segments": [
    {
      "s": "Subject: Can't afford to fail a pharmacovigilance audit or inspection? Read on to find out more",
      "t": "Subjek: Tidak ingin gagal dalam audit atau inspeksi pharmacovigilance? Baca lebih lanjut untuk mengetahui selengkapnya",
      "c": 0.92,
      "m": "Email subject line - standalone marketing hook",
      "sl": 1,
      "tl": 1
    },
    {
      "s": "Dear XXX,",
      "t": "XXX yang terhormat,",
      "c": 0.98,
      "m": "Salutation - standard email opening",
      "sl": 2,
      "tl": 2
    },
    {
      "s": "For the last 3 months, I spoken to over 100 pharmacovigilance professionals and identified 3 key challenges the industry faced.",
      "t": "Dalam 3 bulan terakhir, saya telah berdiskusi dengan lebih dari 100 profesional di bidang pharmacovigilance, dan menengarai 3 tantangan utama yang dihadapi industri.",
      "c": 0.93,
      "m": "Introduction establishing credibility and context",
      "sl": 3,
      "tl": 3
    },
    {
      "s": "They are:",
      "t": "Tantangan tersebut adalah:",
      "c": 0.95,
      "m": "List introduction - transitional phrase",
      "sl": 3,
      "tl": 3
    },
    {
      "s": "Improving the pharmacovigilance audit and inspection preparation",
      "t": "Memperbaiki persiapan audit dan inspeksi pharmacovigilance",
      "c": 0.94,
      "m": "First challenge in list",
      "sl": 4,
      "tl": 4
    },
    {
      "s": "Planning and managing risks and adverse drug reactions in a more effective manner",
      "t": "Merencanakan dan mengelola risiko dan reaksi obat yang buruk dengan cara yang lebih efektif",
      "c": 0.93,
      "m": "Second challenge in list",
      "sl": 5,
      "tl": 5
    },
    {
      "s": "Strategically adapting your current strategies and processes to the latest Asia pharmacoviglance regulations and the new EU legislations",
      "t": "Mengadaptasi strategi dan proses saat ini secara strategis terhadap regulasi pharmacovigilance terkini di Asia dan legislasi UE yang baru",
      "c": 0.92,
      "m": "Third challenge in list",
      "sl": 6,
      "tl": 6
    },
    {
      "s": "If the above are the same 3 challenges you face and would like to find out what your industry peers are doing to overcome them, then you will love the 4th Annual Phamacovigilance Asia Summit!",
      "t": "Jika hal di atas merupakan 3 tantangan yang juga Anda hadapi, dan Anda ingin mengetahui apa yang dilakukan para pelaku industri lain dalam mengatasinya, Anda akan menyukai 4th Annual Phamacovigilance Asia Summit (KTT Asia Tahunan Ke-4 mengenai Pharmacovigilance)!",
      "c": 0.91,
      "m": "Value proposition connecting challenges to the event",
      "sl": 7,
      "tl": 7
    },
    {
      "s": "We understand the importance of information practicality and hence have collated the most useful pharamcovigilance tips and perspectives in the industry in a concise event format, so that you can relate to them and derive the most benefit out of it.",
      "t": "Kami paham akan pentingnya informasi yang praktis, dan karena itu kami telah menghimpun tips dan perspektif pharmacovigilance paling bermanfaat dalam format acara yang ringkas, sehingga Anda dapat menangkap dan memperoleh manfaat optimal darinya.",
      "c": 0.92,
      "m": "Event value description - benefits explanation",
      "sl": 8,
      "tl": 8
    },
    {
      "s": "Plus, to help you maximize your time out of office, 5 specially constructed workshops that will look at best practices in overcoming key issues raised above are available for your selection.",
      "t": "Selain itu, untuk membantu memaksimalkan waktu Anda di luar tempat kerja, telah tersedia 5 lokakarya khusus yang akan membahas praktik terbaik dalam menanggulangi isu-isu penting yang dikemukakan di atas.",
      "c": 0.93,
      "m": "Workshop offering description",
      "sl": 10,
      "tl": 10
    },
    {
      "s": "Don't miss them! Click here to find out more about the workshops.",
      "t": "Jangan lewatkan! Klik di sini untuk mengetahui lebih lanjut tentang lokakarya tersebut.",
      "c": 0.94,
      "m": "Urgent call to action for workshops",
      "sl": 10,
      "tl": 10
    },
    {
      "s": "I look forward to seeing you in Singapore this June!",
      "t": "Saya nanti kehadiran Anda di Singapura bulan Juni ini!",
      "c": 0.95,
      "m": "Closing anticipation statement",
      "sl": 11,
      "tl": 16
    },
    {
      "s": "Yours sincerely,",
      "t": "Hormat saya,",
      "c": 0.97,
      "m": "Formal closing",
      "sl": 12,
      "tl": 17
    },
    {
      "s": "xxx",
      "t": "xxx",
      "c": 0.99,
      "m": "Name placeholder",
      "sl": 13,
      "tl": 18
    },
    {
      "s": "Yip Teck Chee",
      "t": "Yip Teck Chee",
      "c": 0.99,
      "m": "Signature name",
      "sl": 14,
      "tl": 19
    },
    {
      "s": "Conference Director",
      "t": "Conference Director",
      "c": 0.99,
      "m": "Title",
      "sl": 15,
      "tl": 20
    },
    {
      "s": "Pharma IQ – A Division of IQPC Worldwide",
      "t": "Pharma IQ – Divisi dari IQPC Worldwide",
      "c": 0.96,
      "m": "Company affiliation",
      "sl": 16,
      "tl": 21
    }
  ]
}
```


ET0020_Mm Email - Primary.en-SG_ja-JP.L1-T1

```json
{
  "combined_segments": [
    {
      "s": "For the last 3 months, I spoken to over 100 pharmacovigilance professionals and identified 3 key challenges the industry faced. They are:",
      "t": "去る３ヶ月間、私は100名を超える医薬品安全性監視の専門家から話を聞き、この業界が直面している3つの主要課題を認識しました。以下の課題です。",
      "c": 0.95,
      "m": "Combined because the second sentence 'They are:' is a direct continuation and introduction to the list that follows, forming a complete thought unit",
      "sl": 3,
      "tl": 3
    },
    {
      "s": "You know that the negative implications for a poorly constructed pharmacovigilance framework and strategy is tremendous. The 4th Annual Pharmcovigilance Asia Summit is aimed at helping you to do your job better and faster. Download the summit brochure here.",
      "t": "ご存知の通り、医薬品安全性監視の拙劣な枠組みや戦略によるマイナスの影響は非常に大きいです。第4回年次医薬品安全性監視アジアサミットは、皆さまの業務をより円滑化することを目的としています。こちらからサミットのパンフレットをダウンロードしてください。",
      "c": 0.9,
      "m": "Combined because these three sentences form a coherent argument: problem statement → solution → call to action",
      "sl": 9,
      "tl": 9
    },
    {
      "s": "P.S. Take advantage of our early bird offer! Save up to xxx when you book and pay before xxxxx! PPS Want to book in groups of 3 or more? Email us at enquiry@iqpc.com.sg to find out about group discounts available",
      "t": "P.S.早割キャンペーンをご利用ください！xxxxxまでにご予約・お支払いただくと、最大xxxの割引になります。３名以上でご予約される場合、グループ割引が適用されます。グループ割引の詳細は、メールにてenquiry@iqpc.com.sgにお問い合わせください。",
      "c": 0.92,
      "m": "Combined because both P.S. and PPS sections contain promotional offers and form a single promotional unit at the end of the email",
      "sl": 17,
      "tl": 20
    }
  ],
  "combined_segments_split": [
    {
      "s": "For the last 3 months, I spoken to over 100 pharmacovigilance professionals and identified 3 key challenges the industry faced.",
      "t": "去る３ヶ月間、私は100名を超える医薬品安全性監視の専門家から話を聞き、この業界が直面している3つの主要課題を認識しました。",
      "c": 0.95,
      "m": "Split from combined segment - main statement",
      "sl": 3,
      "tl": 3
    },
    {
      "s": "They are:",
      "t": "以下の課題です。",
      "c": 0.95,
      "m": "Split from combined segment - introduction to list",
      "sl": 3,
      "tl": 3
    },
    {
      "s": "You know that the negative implications for a poorly constructed pharmacovigilance framework and strategy is tremendous.",
      "t": "ご存知の通り、医薬品安全性監視の拙劣な枠組みや戦略によるマイナスの影響は非常に大きいです。",
      "c": 0.9,
      "m": "Split from combined segment - problem statement",
      "sl": 9,
      "tl": 9
    },
    {
      "s": "The 4th Annual Pharmcovigilance Asia Summit is aimed at helping you to do your job better and faster.",
      "t": "第4回年次医薬品安全性監視アジアサミットは、皆さまの業務をより円滑化することを目的としています。",
      "c": 0.9,
      "m": "Split from combined segment - solution presentation",
      "sl": 9,
      "tl": 9
    },
    {
      "s": "Download the summit brochure here.",
      "t": "こちらからサミットのパンフレットをダウンロードしてください。",
      "c": 0.9,
      "m": "Split from combined segment - call to action",
      "sl": 9,
      "tl": 9
    },
    {
      "s": "P.S. Take advantage of our early bird offer!",
      "t": "P.S.早割キャンペーンをご利用ください！",
      "c": 0.92,
      "m": "Split from combined segment - early bird offer",
      "sl": 17,
      "tl": 20
    },
    {
      "s": "Save up to xxx when you book and pay before xxxxx!",
      "t": "xxxxxまでにご予約・お支払いただくと、最大xxxの割引になります。",
      "c": 0.92,
      "m": "Split from combined segment - early bird details",
      "sl": 17,
      "tl": 20
    },
    {
      "s": "PPS Want to book in groups of 3 or more?",
      "t": "３名以上でご予約される場合、グループ割引が適用されます。",
      "c": 0.92,
      "m": "Split from combined segment - group booking question",
      "sl": 18,
      "tl": 21
    },
    {
      "s": "Email us at enquiry@iqpc.com.sg to find out about group discounts available",
      "t": "グループ割引の詳細は、メールにてenquiry@iqpc.com.sgにお問い合わせください。",
      "c": 0.92,
      "m": "Split from combined segment - group discount contact",
      "sl": 18,
      "tl": 21
    }
  ],
  "sentence_segments": [
    {
      "s": "Subject: Can't afford to fail a pharmacovigilance audit or inspection? Read on to find out more",
      "t": "件名：医薬品安全性監視の監査・検査の失敗はもう許されない？詳細をご覧ください",
      "c": 0.95,
      "m": "Email subject line - standalone unit",
      "sl": 1,
      "tl": 1
    },
    {
      "s": "Dear XXX,",
      "t": "XXX 様",
      "c": 0.98,
      "m": "Salutation - standalone greeting",
      "sl": 2,
      "tl": 2
    },
    {
      "s": "Improving the pharmacovigilance audit and inspection preparation",
      "t": "医薬品安全性監視の監査および検査準備の向上",
      "c": 0.96,
      "m": "List item 1 - individual bullet point",
      "sl": 4,
      "tl": 4
    },
    {
      "s": "Planning and managing risks and adverse drug reactions in a more effective manner",
      "t": "医薬品のリスクおよび副作用に対するより効率的な計画と管理",
      "c": 0.95,
      "m": "List item 2 - individual bullet point",
      "sl": 5,
      "tl": 5
    },
    {
      "s": "Strategically adapting your current strategies and processes to the latest Asia pharmacoviglance regulations and the new EU legislations",
      "t": "アジアにおける最新の医薬品安全性監視規則および最新のEU規則への現行の方策・処理の戦略的適合",
      "c": 0.94,
      "m": "List item 3 - individual bullet point",
      "sl": 6,
      "tl": 6
    },
    {
      "s": "If the above are the same 3 challenges you face and would like to find out what your industry peers are doing to overcome them, then you will love the 4th Annual Phamacovigilance Asia Summit!",
      "t": "まさにこの３つの課題に直面し、これらの課題に対する業界内の取り組みにご興味をお持ちであれば、ぜひ第4回年次医薬品安全性監視アジアサミットにご参加ください。",
      "c": 0.93,
      "m": "Conditional statement and invitation - complete thought",
      "sl": 7,
      "tl": 7
    },
    {
      "s": "We understand the importance of information practicality and hence have collated the most useful pharamcovigilance tips and perspectives in the industry in a concise event format, so that you can relate to them and derive the most benefit out of it.",
      "t": "医薬品安全性監視に関する有益な情報と業界の展望を簡潔にまとめてご紹介し、皆さまに実際にご活用いただける実用性の高い情報をご提供します。",
      "c": 0.92,
      "m": "Value proposition statement - complete sentence",
      "sl": 8,
      "tl": 8
    },
    {
      "s": "Plus, to help you maximize your time out of office, 5 specially constructed workshops that will look at best practices in overcoming key issues raised above are available for your selection.",
      "t": "また、この機会を最大限に活かしていただくために、主要な課題に対するベストプラクティスを考察するための5つの特別ワークショップをご用意しており、ご希望に応じて受講いただけます。",
      "c": 0.91,
      "m": "Workshop offering - complete sentence",
      "sl": 10,
      "tl": 10
    },
    {
      "s": "Don't miss them!",
      "t": "ぜひご参加ください。",
      "c": 0.94,
      "m": "Urgency call - standalone exclamation",
      "sl": 10,
      "tl": 10
    },
    {
      "s": "Click here to find out more about the workshops.",
      "t": "ワークショップの詳しい情報は、こちらをクリックしてください。",
      "c": 0.95,
      "m": "Call to action for workshops - complete instruction",
      "sl": 10,
      "tl": 10
    },
    {
      "s": "I look forward to seeing you in Singapore this June!",
      "t": "６月にシンガポールでお会いするのを楽しみにしています。",
      "c": 0.96,
      "m": "Closing anticipation - complete sentence",
      "sl": 11,
      "tl": 16
    },
    {
      "s": "Yours sincerely,",
      "t": "",
      "c": 0.98,
      "m": "Closing salutation - standalone",
      "sl": 12,
      "tl": 17
    },
    {
      "s": "xxx",
      "t": "xxx",
      "c": 0.99,
      "m": "Name placeholder - standalone",
      "sl": 13,
      "tl": 17
    },
    {
      "s": "Yip Teck Chee",
      "t": "イップ・テック・チー",
      "c": 0.98,
      "m": "Name - standalone",
      "sl": 14,
      "tl": 18
    },
    {
      "s": "Conference Director",
      "t": "カンファレンス責任者",
      "c": 0.97,
      "m": "Title - standalone",
      "sl": 15,
      "tl": 18
    },
    {
      "s": "Pharma IQ – A Division of IQPC Worldwide",
      "t": "Pharma IQ  – IQPC Worldwide部門",
      "c": 0.97,
      "m": "Company affiliation - standalone",
      "sl": 16,
      "tl": 19
    }
  ]
}
```


ET0020_Mm Email - Primary.en-SG_ko-KR.L1-T1

```json
{
  "combined_segments": [
    {
      "s": "For the last 3 months, I spoken to over 100 pharmacovigilance professionals and identified 3 key challenges the industry faced. They are:",
      "t": "지난 3개월간 100명 이상의 약물감시 전문가와 면담을 하였고, 현재 우리 업계가 직면하고 있는 세 가지 주요 과제를 확인할 수 있었습니다. 그 과제는 다음과 같습니다.",
      "c": 0.95,
      "m": "Combined because the second sentence directly refers to and completes the first sentence's thought about the identified challenges",
      "sl": 3,
      "tl": 3
    },
    {
      "s": "You know that the negative implications for a poorly constructed pharmacovigilance framework and strategy is tremendous. The 4th Annual Pharmcovigilance Asia Summit is aimed at helping you to do your job better and faster. Download the summit brochure here.",
      "t": "아시다시피, 부실한 약물감시 체계와 전략은 그 부정적인 영향으로 막대한 손실을 끼치게 됩니다. 제4차 연례 약물감시 아시아 회담의 목적은 여러분의 업무를 더욱 효과적이고, 신속하게 처리할 수 있도록 돕는 것입니다. 관련 정보는 회담 브로셔를 다운로드하시기 바랍니다.",
      "c": 0.9,
      "m": "Combined because these three sentences form a coherent argument: problem statement → solution → call to action",
      "sl": 9,
      "tl": 9
    }
  ],
  "combined_segments_split": [
    {
      "s": "For the last 3 months, I spoken to over 100 pharmacovigilance professionals and identified 3 key challenges the industry faced.",
      "t": "지난 3개월간 100명 이상의 약물감시 전문가와 면담을 하였고, 현재 우리 업계가 직면하고 있는 세 가지 주요 과제를 확인할 수 있었습니다.",
      "c": 0.95,
      "m": "Split from combined segment - research findings",
      "sl": 3,
      "tl": 3
    },
    {
      "s": "They are:",
      "t": "그 과제는 다음과 같습니다.",
      "c": 0.95,
      "m": "Split from combined segment - introduction to list",
      "sl": 3,
      "tl": 3
    },
    {
      "s": "You know that the negative implications for a poorly constructed pharmacovigilance framework and strategy is tremendous.",
      "t": "아시다시피, 부실한 약물감시 체계와 전략은 그 부정적인 영향으로 막대한 손실을 끼치게 됩니다.",
      "c": 0.9,
      "m": "Split from combined segment - problem statement",
      "sl": 9,
      "tl": 9
    },
    {
      "s": "The 4th Annual Pharmcovigilance Asia Summit is aimed at helping you to do your job better and faster.",
      "t": "제4차 연례 약물감시 아시아 회담의 목적은 여러분의 업무를 더욱 효과적이고, 신속하게 처리할 수 있도록 돕는 것입니다.",
      "c": 0.9,
      "m": "Split from combined segment - solution presentation",
      "sl": 9,
      "tl": 9
    },
    {
      "s": "Download the summit brochure here.",
      "t": "관련 정보는 회담 브로셔를 다운로드하시기 바랍니다.",
      "c": 0.9,
      "m": "Split from combined segment - call to action",
      "sl": 9,
      "tl": 9
    }
  ],
  "sentence_segments": [
    {
      "s": "Subject: Can't afford to fail a pharmacovigilance audit or inspection? Read on to find out more",
      "t": "제목: 약물감시 감사나 검사가 중요하다고 생각하십니까? 자세한 내용 살펴보기",
      "c": 0.85,
      "m": "Email subject line - single sentence unit",
      "sl": 1,
      "tl": 1
    },
    {
      "s": "Dear XXX,",
      "t": "XXX 귀하,",
      "c": 0.95,
      "m": "Salutation - single unit",
      "sl": 2,
      "tl": 2
    },
    {
      "s": "Improving the pharmacovigilance audit and inspection preparation",
      "t": "약물감시 감사 및 검사 준비 과정의 개선 필요",
      "c": 0.9,
      "m": "First challenge - list item",
      "sl": 4,
      "tl": 4
    },
    {
      "s": "Planning and managing risks and adverse drug reactions in a more effective manner",
      "t": "더욱 효과적인 방법으로 위험과 약물 유해 반응의 관리 및 계획 필요",
      "c": 0.9,
      "m": "Second challenge - list item",
      "sl": 5,
      "tl": 5
    },
    {
      "s": "Strategically adapting your current strategies and processes to the latest Asia pharmacoviglance regulations and the new EU legislations",
      "t": "최신 아시아 약물감시 규정 및 새로운 EU 법안에 맞게 현재 전략과 절차의 전략적인 조정 필요",
      "c": 0.9,
      "m": "Third challenge - list item",
      "sl": 6,
      "tl": 6
    },
    {
      "s": "If the above are the same 3 challenges you face and would like to find out what your industry peers are doing to overcome them, then you will love the 4th Annual Phamacovigilance Asia Summit!",
      "t": "이 세 가지 과제로 고민하고 있다면 그리고 다른 업계 종사자들이 이 문제를 어떻게 극복하고 있는지 알고 싶다면, 제4차 연례 약물감시 아시아 회담에 참가하십시오.",
      "c": 0.9,
      "m": "Conditional invitation - single complex sentence",
      "sl": 7,
      "tl": 7
    },
    {
      "s": "We understand the importance of information practicality and hence have collated the most useful pharamcovigilance tips and perspectives in the industry in a concise event format, so that you can relate to them and derive the most benefit out of it.",
      "t": "실제로 도움이 되는 정보를 드리는 것이 중요하단 생각에, 업계에서 가장 유용한 약물감시 정보와 각기 다른 의견을 한자리에 모았으며, 여러분에게 큰 도움이 되리라 생각합니다.",
      "c": 0.85,
      "m": "Event value proposition - single complex sentence",
      "sl": 8,
      "tl": 8
    },
    {
      "s": "Plus, to help you maximize your time out of office, 5 specially constructed workshops that will look at best practices in overcoming key issues raised above are available for your selection.",
      "t": "또한 이번 행사가 더욱 유익한 시간이 될 수 있도록, 앞서 제시한 문제에 대처하는 모범사례를 살펴보는 시간도 마련되어 있으며5가지 특별 구성 워크숍 중 선택하시면 됩니다.",
      "c": 0.85,
      "m": "Workshop offering - single sentence",
      "sl": 10,
      "tl": 10
    },
    {
      "s": "Don't miss them!",
      "t": "이번 기회를 놓치지 마십시오!",
      "c": 0.95,
      "m": "Urgency call - single exclamation",
      "sl": 10,
      "tl": 10
    },
    {
      "s": "Click here to find out more about the workshops.",
      "t": "워크숍에 대한 자세한 내용은 여기를 클릭하십시오.",
      "c": 0.95,
      "m": "Call to action - single instruction",
      "sl": 10,
      "tl": 10
    },
    {
      "s": "I look forward to seeing you in Singapore this June!",
      "t": "올 6월에 싱가포르에서 만나 뵙기를 기대합니다!",
      "c": 0.95,
      "m": "Closing anticipation - single sentence",
      "sl": 11,
      "tl": 16
    },
    {
      "s": "Yours sincerely,",
      "t": "감사합니다.",
      "c": 0.9,
      "m": "Closing salutation - single unit",
      "sl": 12,
      "tl": 17
    },
    {
      "s": "xxx",
      "t": "xxx",
      "c": 1.0,
      "m": "Name placeholder - single unit",
      "sl": 13,
      "tl": 18
    },
    {
      "s": "Yip Teck Chee",
      "t": "Yip Teck Chee",
      "c": 1.0,
      "m": "Name - single unit",
      "sl": 14,
      "tl": 19
    },
    {
      "s": "Conference Director",
      "t": "회의 총괄 진행자",
      "c": 0.95,
      "m": "Title - single unit",
      "sl": 15,
      "tl": 20
    },
    {
      "s": "Pharma IQ – A Division of IQPC Worldwide",
      "t": "Pharma IQ - IQPC Worldwide 사업부",
      "c": 0.95,
      "m": "Company affiliation - single unit",
      "sl": 16,
      "tl": 21
    },
    {
      "s": "P.S. Take advantage of our early bird offer! Save up to xxx when you book and pay before xxxxx!",
      "t": "추신 조기 등록 시 할인 혜택이 있습니다! xxxxx 전에 예약하고 참가비를 납부하시면 최대 xxx이 할인됩니다.",
      "c": 0.9,
      "m": "PS with promotional offer - single coherent thought",
      "sl": 17,
      "tl": 22
    },
    {
      "s": "PPS Want to book in groups of 3 or more? Email us at enquiry@iqpc.com.sg to find out about group discounts available",
      "t": "추추신 3인 이상 단체 예약을 원하십니까? enquiry@iqpc.com.sg로 이메일을 보내주시면 단체 할인에 대해 자세히 알려드립니다.",
      "c": 0.9,
      "m": "PPS with group booking information - single coherent thought",
      "sl": 18,
      "tl": 23
    }
  ]
}
```


ET0020_Mm Email - Primary.en-SG_zh-CN.L1-T1

```json
{
  "combined_segments": [
    {
      "s": "For the last 3 months, I spoken to over 100 pharmacovigilance professionals and identified 3 key challenges the industry faced. They are:",
      "t": "过去三个月来，我同 100 多位药物警戒专业人士进行了交谈并确定了本行业所面临的 3 项关键挑战。它们是：",
      "c": 0.95,
      "m": "Combined because the second sentence directly refers to and completes the first sentence's thought about identifying challenges",
      "sl": 3,
      "tl": 3
    },
    {
      "s": "Improving the pharmacovigilance audit and inspection preparation\nPlanning and managing risks and adverse drug reactions in a more effective manner\nStrategically adapting your current strategies and processes to the latest Asia pharmacoviglance regulations and the new EU legislations",
      "t": "改进药物警戒审核和检验的准备工作\n以更有效的方式制定计划并管理风险和药物不良反应\n从战略的角度使您当前的策略和程序与最新的亚洲药物警戒法规和欧盟新立法相适应。",
      "c": 0.92,
      "m": "Combined as these are three bullet points that form a cohesive list of challenges, maintaining the parallel structure",
      "sl": 6,
      "tl": 6
    },
    {
      "s": "We understand the importance of information practicality and hence have collated the most useful pharamcovigilance tips and perspectives in the industry in a concise event format, so that you can relate to them and derive the most benefit out of it.",
      "t": "我们认识到了实用信息的重要性，因此我们通过简明扼要的会议方式来提供业内最有用的药物警戒提示和观点，以便您能将它们联系起来并从从获得最大的收益。",
      "c": 0.9,
      "m": "Combined as this is a single complex sentence with cause-effect relationship that should be preserved",
      "sl": 8,
      "tl": 8
    },
    {
      "s": "You know that the negative implications for a poorly constructed pharmacovigilance framework and strategy is tremendous. The 4th Annual Pharmcovigilance Asia Summit is aimed at helping you to do your job better and faster. Download the summit brochure here.",
      "t": "众所周知，不良的药物警戒框架和策略所造成的负面影响是非常巨大的。第4届亚洲药物警戒峰会旨在帮助您更好、更快地开展您的工作。请在此下载峰会宣传册。",
      "c": 0.88,
      "m": "Combined because these three sentences form a logical progression: problem statement → solution → call to action",
      "sl": 9,
      "tl": 9
    },
    {
      "s": "Plus, to help you maximize your time out of office, 5 specially constructed workshops that will look at best practices in overcoming key issues raised above are available for your selection. Don't miss them! Click here to find out more about the workshops.",
      "t": "另外，为帮助最大限度地利用您的时间，您还可以选择参加 5 场专门设计的研讨会，这些研讨会将探讨解决上述关键问题的最佳实践。机会不容错过!点击此处详细了解这些研讨会。",
      "c": 0.91,
      "m": "Combined as these sentences form a complete promotional unit about workshop offerings with a call to action",
      "sl": 10,
      "tl": 10
    },
    {
      "s": "P.S. Take advantage of our early bird offer! Save up to xxx when you book and pay before xxxxx!\nPPS Want to book in groups of 3 or more? Email us at enquiry@iqpc.com.sg to find out about group discounts available",
      "t": "附言：请利用我们的提前预订优惠计划！在xxxxx之前预订并付款，最多可节省xxx!\n附言：想进行 3 人或 3 人以上的团体预订吗?请发送电邮至enquiry@iqpc.com.sg，了解可用的团体折扣优惠",
      "c": 0.93,
      "m": "Combined as these are two postscript sections that serve similar promotional purposes and should be treated as a unit",
      "sl": 18,
      "tl": 23
    }
  ],
  "combined_segments_split": [
    {
      "s": "For the last 3 months, I spoken to over 100 pharmacovigilance professionals and identified 3 key challenges the industry faced.",
      "t": "过去三个月来，我同 100 多位药物警戒专业人士进行了交谈并确定了本行业所面临的 3 项关键挑战。",
      "c": 0.95,
      "m": "Split from combined segment - main statement",
      "sl": 3,
      "tl": 3
    },
    {
      "s": "They are:",
      "t": "它们是：",
      "c": 0.95,
      "m": "Split from combined segment - introduction to list",
      "sl": 3,
      "tl": 3
    },
    {
      "s": "Improving the pharmacovigilance audit and inspection preparation",
      "t": "改进药物警戒审核和检验的准备工作",
      "c": 0.92,
      "m": "Split from combined segment - first challenge",
      "sl": 4,
      "tl": 4
    },
    {
      "s": "Planning and managing risks and adverse drug reactions in a more effective manner",
      "t": "以更有效的方式制定计划并管理风险和药物不良反应",
      "c": 0.92,
      "m": "Split from combined segment - second challenge",
      "sl": 5,
      "tl": 5
    },
    {
      "s": "Strategically adapting your current strategies and processes to the latest Asia pharmacoviglance regulations and the new EU legislations",
      "t": "从战略的角度使您当前的策略和程序与最新的亚洲药物警戒法规和欧盟新立法相适应。",
      "c": 0.92,
      "m": "Split from combined segment - third challenge",
      "sl": 6,
      "tl": 6
    },
    {
      "s": "You know that the negative implications for a poorly constructed pharmacovigilance framework and strategy is tremendous.",
      "t": "众所周知，不良的药物警戒框架和策略所造成的负面影响是非常巨大的。",
      "c": 0.88,
      "m": "Split from combined segment - problem statement",
      "sl": 9,
      "tl": 9
    },
    {
      "s": "The 4th Annual Pharmcovigilance Asia Summit is aimed at helping you to do your job better and faster.",
      "t": "第4届亚洲药物警戒峰会旨在帮助您更好、更快地开展您的工作。",
      "c": 0.88,
      "m": "Split from combined segment - solution",
      "sl": 9,
      "tl": 9
    },
    {
      "s": "Download the summit brochure here.",
      "t": "请在此下载峰会宣传册。",
      "c": 0.88,
      "m": "Split from combined segment - call to action",
      "sl": 9,
      "tl": 9
    },
    {
      "s": "Plus, to help you maximize your time out of office, 5 specially constructed workshops that will look at best practices in overcoming key issues raised above are available for your selection.",
      "t": "另外，为帮助最大限度地利用您的时间，您还可以选择参加 5 场专门设计的研讨会，这些研讨会将探讨解决上述关键问题的最佳实践。",
      "c": 0.91,
      "m": "Split from combined segment - workshop description",
      "sl": 10,
      "tl": 10
    },
    {
      "s": "Don't miss them!",
      "t": "机会不容错过!",
      "c": 0.91,
      "m": "Split from combined segment - urgency statement",
      "sl": 10,
      "tl": 10
    },
    {
      "s": "Click here to find out more about the workshops.",
      "t": "点击此处详细了解这些研讨会。",
      "c": 0.91,
      "m": "Split from combined segment - call to action",
      "sl": 10,
      "tl": 10
    },
    {
      "s": "P.S. Take advantage of our early bird offer! Save up to xxx when you book and pay before xxxxx!",
      "t": "附言：请利用我们的提前预订优惠计划！在xxxxx之前预订并付款，最多可节省xxx!",
      "c": 0.93,
      "m": "Split from combined segment - first postscript",
      "sl": 17,
      "tl": 22
    },
    {
      "s": "PPS Want to book in groups of 3 or more? Email us at enquiry@iqpc.com.sg to find out about group discounts available",
      "t": "附言：想进行 3 人或 3 人以上的团体预订吗?请发送电邮至enquiry@iqpc.com.sg，了解可用的团体折扣优惠",
      "c": 0.93,
      "m": "Split from combined segment - second postscript",
      "sl": 18,
      "tl": 23
    }
  ],
  "sentence_segments": [
    {
      "s": "Subject: Can't afford to fail a pharmacovigilance audit or inspection? Read on to find out more",
      "t": "主题：想要顺利通过药物警戒审核或检验吗？请阅读以下内容了解详情",
      "c": 0.9,
      "m": "Subject line with question and call to action",
      "sl": 1,
      "tl": 1
    },
    {
      "s": "Dear XXX,",
      "t": "尊敬的XXX：",
      "c": 0.98,
      "m": "Salutation",
      "sl": 2,
      "tl": 2
    },
    {
      "s": "If the above are the same 3 challenges you face and would like to find out what your industry peers are doing to overcome them, then you will love the 4th Annual Phamacovigilance Asia Summit!",
      "t": "如果您也面临着上述三项挑战并且想了解业界同行是如何克服这些挑战的，那么您一定希望参加第 4 届亚洲药物警戒峰会!",
      "c": 0.92,
      "m": "Conditional statement leading to summit promotion",
      "sl": 7,
      "tl": 7
    },
    {
      "s": "I look forward to seeing you in Singapore this June!",
      "t": "我期待着今年六月在新加坡见到您!",
      "c": 0.96,
      "m": "Closing anticipation statement",
      "sl": 11,
      "tl": 16
    },
    {
      "s": "Yours sincerely,",
      "t": "致礼",
      "c": 0.97,
      "m": "Closing salutation",
      "sl": 12,
      "tl": 17
    },
    {
      "s": "xxx",
      "t": "xxx",
      "c": 0.99,
      "m": "Name placeholder",
      "sl": 13,
      "tl": 18
    },
    {
      "s": "Yip Teck Chee",
      "t": "Yip Teck Chee",
      "c": 0.99,
      "m": "Name",
      "sl": 14,
      "tl": 19
    },
    {
      "s": "Conference Director",
      "t": "会务总监",
      "c": 0.95,
      "m": "Title",
      "sl": 15,
      "tl": 20
    },
    {
      "s": "Pharma IQ – A Division of IQPC Worldwide",
      "t": "Pharma IQ – 隶属于 IQPC Worldwide",
      "c": 0.94,
      "m": "Company affiliation",
      "sl": 16,
      "tl": 21
    },
    {
      "s": "报名参加本次会议的四种简单方法：",
      "t": "报名参加本次会议的四种简单方法：",
      "c": 0.99,
      "m": "Additional target-only content - registration methods header",
      "sl": 11,
      "tl": 11
    },
    {
      "s": "回复此电子邮件",
      "t": "回复此电子邮件",
      "c": 0.99,
      "m": "Additional target-only content - registration method 1",
      "sl": 11,
      "tl": 12
    },
    {
      "s": "通过 www.pharmacovigilanceasia.com在线报名",
      "t": "通过 www.pharmacovigilanceasia.com在线报名",
      "c": 0.99,
      "m": "Additional target-only content - registration method 2",
      "sl": 11,
      "tl": 13
    },
    {
      "s": "致电+6567229388",
      "t": "致电+6567229388",
      "c": 0.99,
      "m": "Additional target-only content - registration method 3",
      "sl": 11,
      "tl": 14
    },
    {
      "s": "使用电邮（enquiry@iqpc.com.sg）联系我们",
      "t": "使用电邮（enquiry@iqpc.com.sg）联系我们",
      "c": 0.99,
      "m": "Additional target-only content - registration method 4",
      "sl": 11,
      "tl": 15
    }
  ]
}
```


ET0020_Mm Email - Vendor.en-SG_id-ID.L1-T1

```json
{
  "combined_segments": [
    {
      "s": "Our attendees are made up of pharamcovigilance, drug safety and medical affairs heads that are actively looking for a change of solution/purchasing new solutions. Our attendees are made up of only decision makers from global and Asian pharmaceutical and biotechnology companies. Our attendees are not familiar with solutions in the market, and are using our event to shortlist solutions – you simply need to be there.",
      "t": "Para peserta kami terdiri dari kepala bidang pharmacovigilance, drug safety, dan medical affairs yang secara aktif mencari perubahan solusi/mengejar solusi-solusi baru. Para peserta kami hanya terdiri dari pengambil keputusan dari perusahaan-perusahaan farmasi dan bioteknologi Asia dan global. Para peserta kami tidak akrab dengan solusi-solusi yang ada di pasaran, dan menggunakan program kami untuk memilih solusi terbaik – Anda hanya perlu hadir di sana.",
      "c": 0.95,
      "m": "Combined three consecutive sentences about attendee profiles and needs as they form a coherent thematic unit describing the target audience characteristics",
      "sl": 14,
      "tl": 14
    },
    {
      "s": "Our event provide the best of both worlds – superb content and fantastic networking opportunities. Our event is formatted in a manner that ensure everyone stays throughout the 2 day conference – no more people leaving without you having a chance to speak to them!",
      "t": "Program kami menawarkan yang terbaik dari kedua sisi – konten yang sangat bermutu dan peluang berjejaring yang luar biasa. Program kami disusun dalam format sedemikian rupa sehingga setiap orang dijamin akan tetap betah dalam konferensi yang berlangsung selama 2 hari – tidak akan ada orang yang pergi begitu saja tanpa ada kesempatan bagi Anda untuk berbicara dengannya!",
      "c": 0.92,
      "m": "Combined two sentences describing event benefits as they complement each other in presenting the value proposition",
      "sl": 16,
      "tl": 16
    },
    {
      "s": "Membalas email ini. Online melalui www.pharmacovigilanceasia.com. Hubungi kami di nomor +6567229388. Kirim email ke enquiry@iqpc.com.sg.",
      "t": "Membalas email ini. Online melalui www.pharmacovigilanceasia.com. Hubungi kami di nomor +6567229388. Kirim email ke enquiry@iqpc.com.sg.",
      "c": 0.98,
      "m": "Combined four registration methods as they form a cohesive list of options in the target text (note: this is target-only content not present in source)",
      "sl": 19,
      "tl": 22
    }
  ],
  "combined_segments_split": [
    {
      "s": "Our attendees are made up of pharamcovigilance, drug safety and medical affairs heads that are actively looking for a change of solution/purchasing new solutions.",
      "t": "Para peserta kami terdiri dari kepala bidang pharmacovigilance, drug safety, dan medical affairs yang secara aktif mencari perubahan solusi/mengejar solusi-solusi baru.",
      "c": 0.95,
      "m": "Split from combined segment - attendee profile part 1",
      "sl": 12,
      "tl": 12
    },
    {
      "s": "Our attendees are made up of only decision makers from global and Asian pharmaceutical and biotechnology companies.",
      "t": "Para peserta kami hanya terdiri dari pengambil keputusan dari perusahaan-perusahaan farmasi dan bioteknologi Asia dan global.",
      "c": 0.95,
      "m": "Split from combined segment - attendee profile part 2",
      "sl": 13,
      "tl": 13
    },
    {
      "s": "Our attendees are not familiar with solutions in the market, and are using our event to shortlist solutions – you simply need to be there.",
      "t": "Para peserta kami tidak akrab dengan solusi-solusi yang ada di pasaran, dan menggunakan program kami untuk memilih solusi terbaik – Anda hanya perlu hadir di sana.",
      "c": 0.95,
      "m": "Split from combined segment - attendee needs and call to action",
      "sl": 14,
      "tl": 14
    },
    {
      "s": "Our event provide the best of both worlds – superb content and fantastic networking opportunities.",
      "t": "Program kami menawarkan yang terbaik dari kedua sisi – konten yang sangat bermutu dan peluang berjejaring yang luar biasa.",
      "c": 0.92,
      "m": "Split from combined segment - event benefits part 1",
      "sl": 15,
      "tl": 15
    },
    {
      "s": "Our event is formatted in a manner that ensure everyone stays throughout the 2 day conference – no more people leaving without you having a chance to speak to them!",
      "t": "Program kami disusun dalam format sedemikian rupa sehingga setiap orang dijamin akan tetap betah dalam konferensi yang berlangsung selama 2 hari – tidak akan ada orang yang pergi begitu saja tanpa ada kesempatan bagi Anda untuk berbicara dengannya!",
      "c": 0.92,
      "m": "Split from combined segment - event benefits part 2",
      "sl": 16,
      "tl": 16
    },
    {
      "s": "Membalas email ini.",
      "t": "Membalas email ini.",
      "c": 0.98,
      "m": "Split from combined segment - registration method 1",
      "sl": 19,
      "tl": 19
    },
    {
      "s": "Online melalui www.pharmacovigilanceasia.com.",
      "t": "Online melalui www.pharmacovigilanceasia.com.",
      "c": 0.98,
      "m": "Split from combined segment - registration method 2",
      "sl": 20,
      "tl": 20
    },
    {
      "s": "Hubungi kami di nomor +6567229388.",
      "t": "Hubungi kami di nomor +6567229388.",
      "c": 0.98,
      "m": "Split from combined segment - registration method 3",
      "sl": 21,
      "tl": 21
    },
    {
      "s": "Kirim email ke enquiry@iqpc.com.sg.",
      "t": "Kirim email ke enquiry@iqpc.com.sg.",
      "c": 0.98,
      "m": "Split from combined segment - registration method 4",
      "sl": 22,
      "tl": 22
    }
  ],
  "sentence_segments": [
    {
      "s": "Subject: Our attendees cannot afford to fail a pharmacovigilance audit or inspection. Read on to find out more",
      "t": "Subjek: Para peserta kami tidak ingin gagal dalam audit atau inspeksi pharmacovigilance. Baca lebih lanjut untuk mengetahui selengkapnya",
      "c": 0.9,
      "m": "Email subject line with call to action",
      "sl": 1,
      "tl": 1
    },
    {
      "s": "Dear XXX,",
      "t": "XXX yang terhormat,",
      "c": 0.95,
      "m": "Salutation",
      "sl": 2,
      "tl": 2
    },
    {
      "s": "For the last 3 months, I spoken to over 100 pharmacovigilance professionals and identified 4 key challenges the industry faced.",
      "t": "Dalam 3 bulan terakhir, saya telah berdiskusi dengan lebih dari 100 profesional di bidang pharmacovigilance, dan menengarai 4 tantangan utama yang dihadapi industri.",
      "c": 0.92,
      "m": "Introduction establishing credibility and industry challenges",
      "sl": 3,
      "tl": 3
    },
    {
      "s": "They are:",
      "t": "Tantangan tersebut adalah:",
      "c": 0.95,
      "m": "List introduction",
      "sl": 3,
      "tl": 3
    },
    {
      "s": "Improving the pharmacovigilance audit and inspection preparation",
      "t": "Memperbaiki persiapan audit dan inspeksi pharmacovigilance",
      "c": 0.93,
      "m": "Challenge 1",
      "sl": 4,
      "tl": 4
    },
    {
      "s": "Planning and managing risks and adverse drug reactions in a more effective manner",
      "t": "Merencanakan dan mengelola risiko dan reaksi obat yang buruk dengan cara yang lebih efektif",
      "c": 0.93,
      "m": "Challenge 2",
      "sl": 5,
      "tl": 5
    },
    {
      "s": "Adverse drug reaction reporting and monitoring",
      "t": "Pelaporan dan pemantauan reaksi buruk obat",
      "c": 0.93,
      "m": "Challenge 3",
      "sl": 6,
      "tl": 6
    },
    {
      "s": "Strategically adapting your current strategies and processes to the latest Asia pharmacoviglance regulations and the new EU legislations",
      "t": "Mengadaptasi strategi dan proses saat ini secara strategis terhadap regulasi pharmacovigilance terkini di Asia dan legislasi UE yang baru",
      "c": 0.92,
      "m": "Challenge 4",
      "sl": 7,
      "tl": 7
    },
    {
      "s": "Can you help them?",
      "t": "Dapatkah Anda membantu mereka?",
      "c": 0.96,
      "m": "Direct question to engage reader",
      "sl": 8,
      "tl": 8
    },
    {
      "s": "If your answer is YES, then you need to be at the 4th Annual Phamacovigilance Asia Summit!",
      "t": "Jika jawaban Anda adalah YA, maka Anda harus hadir di 4th Annual Phamacovigilance Asia Summit (KTT Asia Tahunan Ke-4 mengenai Pharmacovigilance)!",
      "c": 0.91,
      "m": "Call to action with event mention",
      "sl": 9,
      "tl": 9
    },
    {
      "s": "Why do I say that?",
      "t": "Mengapa saya katakan demikian?",
      "c": 0.95,
      "m": "Rhetorical question to introduce benefits",
      "sl": 10,
      "tl": 10
    },
    {
      "s": "5 Key Reasons:",
      "t": "5 Alasan Utama:",
      "c": 0.96,
      "m": "List introduction for benefits",
      "sl": 11,
      "tl": 11
    },
    {
      "s": "If you are interested to find out more about business opportunities in the Asia pharmacovigilance market, please email me at enquiry@iqpc.com.sg or call +65 6722 9388, so that I can send you the brochure.",
      "t": "Jika Anda ingin mengetahui lebih lanjut tentang peluang bisnis di pasar pharmacovigilance Asia, silakan kirimkan e-mail ke enquiry@iqpc.com.sg atau hubungi +65 6722 9388, sehingga saya dapat mengirimi Anda brosurnya.",
      "c": 0.93,
      "m": "Contact information and call to action",
      "sl": 17,
      "tl": 17
    },
    {
      "s": "Empat Cara Mudah untuk Mendaftar di konferensi ini:",
      "t": "Empat Cara Mudah untuk Mendaftar di konferensi ini:",
      "c": 1.0,
      "m": "Target-only content - registration methods introduction",
      "sl": 18,
      "tl": 18
    },
    {
      "s": "I look forward to seeing you in Singapore this June!",
      "t": "Saya nanti kehadiran Anda di Singapura bulan Juni ini!",
      "c": 0.94,
      "m": "Closing anticipation statement",
      "sl": 23,
      "tl": 23
    },
    {
      "s": "Yours sincerely,",
      "t": "Hormat saya,",
      "c": 0.95,
      "m": "Closing salutation",
      "sl": 24,
      "tl": 24
    },
    {
      "s": "xxx",
      "t": "xxx",
      "c": 1.0,
      "m": "Placeholder name",
      "sl": 25,
      "tl": 25
    },
    {
      "s": "Yip Teck Chee",
      "t": "Yip Teck Chee",
      "c": 1.0,
      "m": "Signature name",
      "sl": 26,
      "tl": 26
    },
    {
      "s": "Conference Director",
      "t": "Conference Director",
      "c": 1.0,
      "m": "Title",
      "sl": 27,
      "tl": 27
    },
    {
      "s": "Pharma IQ – A Division of IQPC Worldwide",
      "t": "Pharma IQ – Divisi dari IQPC Worldwide",
      "c": 0.97,
      "m": "Company affiliation",
      "sl": 28,
      "tl": 28
    },
    {
      "s": "P.S. Take advantage of our early bird offer! Save up to xxx when you book and pay before xxxxx!",
      "t": "N.B. Manfaatkan penawaran istimewa kami! Hemat hingga xxx jika Anda memesan dan membayar sebelum xxxxx!",
      "c": 0.92,
      "m": "Postscript with promotional offer",
      "sl": 29,
      "tl": 29
    },
    {
      "s": "PPS Want to book in groups of 3 or more? Email us at enquiry@iqpc.com.sg to find out about group discounts available",
      "t": "PPS Ingin memesan dalam grup beranggotakan 3 orang atau lebih? Kirimkan e-mail ke enquiry@iqpc.com.sg untuk mengetahui lebih lanjut tentang diskon khusus grup yang tersedia",
      "c": 0.93,
      "m": "Additional postscript for group bookings",
      "sl": 30,
      "tl": 30
    }
  ]
}
```